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Each year, more patients die from lung cancer than die from any other type of 
cancer (1). Non-small cell lung carcinoma (NSCLC) is the most common form of lung 
cancer, accounting for approximately 85% of cases. Developing reliable therapeutics for 
NSCLC has proven to be perniciously difficult, with the 5-year survival rate for 
metastatic NSCLC being less than 5%. Because patients with NSCLC do not typically 
exhibit obvious symptoms, the disease is often not detected in its early stages (2). The 
majority of NSCLC is intrinsically multi-drug resistant. When therapeutics do prove 
effective NSCLC, drug resistance is rapidly acquired. Patients regularly must be put on 
experimental therapies because of the high failure-rate of first-line and second-line 
therapies. And, those experimental therapies themselves often fail. Very few 
experimental therapies make it past the third phase of clinical trialing. Even when 
treatments are effective for NSCLC patients, dosages are often suboptimal because of 
the general intolerability of chemotherapeutics. Chemotherapeutics are commonly 
administered in combination with one or more targeted therapies to reduce the 
necessary dosage of each. This is meant to reduce the number of side-effects from 
chemotherapy the patient must endure (3). 
Mechanistic modeling is an ideal method for making informed decisions in clinical 
trial design, optimizing dosages, and individualizing therapy (4–6). The common 
framework for supporting mathematical modeling of pharmaceuticals is non-linear mixed 
effects modeling (NLME). The kinetic properties of a therapeutic – absorption, 
distribution, metabolism, and elimination – are called pharmacokinetics (PK). The 
biological dynamics resulting from the biodistribution of a pharmaceutical are called 
xi 
pharmacodynamics (PD). Using NLME modeling, one can simultaneously describe both 
the pharmacokinetics and pharmacodynamics of a pharmaceutical, even if the patients 
being modeled have disparate individual characteristics and the sampling schedule is 
sparse. After initially parameterizing a population model, the model can easily be 
updated and expanded by either incorporating new data or further informing the model 
structure with disease biology and therapeutic properties. Parameterized, i.e. fit, models 
can be used to simulate hypothetical clinical trials, giving an approximate answer 
without the costly need for clinical experiments. The more mechanistic the model, the 
more accurate the simulated clinical trials become. As a graduate student, the primary 
aim of the research I have been involved with was to better characterize the PKPD of 
various therapies for NSCLC using population modeling. After fitting the models 
featured in each study, we used simulation to answer questions about optimal dosing 
regimens. Optimizing a dosing regimen reduces the side-effect burden in the patient, 
increases efficacy of the therapy, and – if the drug is still in development – reduces the 
chance that an effective therapy might fail in clinical trials due to an ineffective dosing 
schedule. 
The present body of work is a collection of four papers from my time as a 
graduate student. They nominally demonstrate both in-depth knowledge of modeling 
pharmaceuticals as well as summarize related findings in NSCLC research. 
Concurrently, they were selected to give insight into each stage of population modeling 
relative to clinical pharmaceutical development. After a hypothesis is proposed, 
preclinical modeling is used to develop mathematical descriptions of PKPD, and 
xii 
eventually the model is translated into a clinical setting to answer hypothetical questions 
about therapeutic safety and efficacy.
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CHAPTER 1.    GENERAL INTRODUCTION 
Developing effective therapeutic strategies for non-small lung carcinoma 
(NSCLC) is one of the most pressing needs in pharmacology today. This year, in the 
United States alone, it is estimated that there will be 228,820 new cases of lung cancer 
and 135,720 people will die from lung cancer (2). Cigarettes and other forms of 
combustible recreational products are growing in popularity and they substantially 
increase the risk that a user develops NSCLC. Beyond risk of NSCLC from recreational 
products, several rapidly-expanding industries – including manufacturing, mining, 
farming, transportation, and electricity production – generate a great volume of 
aerosolized carcinogens. Exposure to these industrial air pollutants greatly increases 
the chances that both laborers, as well as fence-line community members, in these 
industries develop NSCLC during their life (7).  
The development rate of therapeutics for NSCLC has been rapidly-accelerating 
in recent decades; many contemporary first-line therapeutic strategies are combination 
therapies. Historically, cutting-edge oncology research focused on refining surgical 
resection of the primary tumor as well as radiology. In the midcentury, the oncology 
community adopted cytotoxics as a concurrent course of treatment with surgery and 
radiology. The impetus for including chemotherapy in the surgical/radiological treatment 
regimen common in oncology was the observation that primary tumor resection did not 
typically save the life of patients. Especially since most patients do not have symptoms 
until the cancer has already metastasized. For most cancer patients, the ultimate 
causes of death are the metastases and as well as micro-infiltration of neoplasms into 
surrounding tissues (8). 
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Cytotoxic therapies are generalized therapies that accumulate in and 
preferentially kill rapidly-dividing cell populations. When used in cancer patients, 
cytotoxics disrupt and limit the growth of tumors, metastases, and micro-infiltration of 
neoplasms into surrounding tissues, increasing the probability of survival after primary 
tumor removal. However, several populations of rapidly-dividing endogenous cells are 
harmed by cytotoxics, e.g. hematopoietic stem cells. This puts hard limits on the 
feasibility of scaling dosages in cytotoxic therapy without the side-effect burden of the 
therapy putting patient survival at risk. Scaling dosages upward is sometimes an option 
for increasing response in patients (9). Accordingly, several adjunct and combination 
therapies involving were developed to increase the efficacy of cytotoxics either 
synergistically or additively. The two primary classes of adjunct therapies in NSCLC are 
targeted therapies and immune-checkpoint inhibitors. Targeted therapies are aimed at 
exploiting unique biological features of cancer physiology to combat the disease. For 
example, bevacizumab attenuates hypoxia signaling from the tumor to the body. In the 
short-term bevacizumab therapy increases the efficiency of drug delivery to the tumor 
by normalizing tumor vasculature, and in the long-term deprives the tumor of oxygen as 
the tumor blood supply recedes. Immune-checkpoint inhibitors instead decrease the 
ability of cancer cells to evade the host immune system. Currently, a broad combination 
of surgery, radiology, chemotherapy, targeted therapy, and immune checkpoint 
inhibitors are employed in treating NSCLC. The diverse array of combination therapies, 
and experimental therapies, being used to treat NSCLC make anti-NSCLC therapeutics 
an ideal target for mathematical modeling studies (4,5,10,11). 
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Building comprehensive population-level, mathematical descriptions of the PKPD 
of a therapeutic allows researchers to accelerate the resolution of important clinical 
hypotheses about pharmaceutical safety and efficacy by simulating virtual clinical trials. 
The statistical framework for population modeling is nonlinear mixed-effects (NLME) 
modeling. NLME modeling of PKPD is especially important with respect to cytotoxic 
drugs – as well as other cancer therapies – for four reasons. First, sampling in cancer 
patients tends to be sparse and noisy, and there is significant variation between 
individual patient pathology. NLME modeling is an ideal framework for pooling and 
performing statistical analysis on a sparsely sampled, noisy, and highly variable dataset 
(12). Second, antiproliferative drugs induce heavy side-effect burdens. With a 
combination of preclinical data and sparse clinical sampling, the dosages which produce 
plasma concentrations over the minimum concentration required to achieve effect and 
below the toxicity threshold (i.e. within the therapeutic window) can be quickly identified. 
Third, research in cancer is extremely resource intensive and prone to failure. 
Therefore, it is important to optimize study design. For experimental therapies, 
optimizing trial design via simulation reduces the chance that an effective therapy would 
fail in clinical trials due to underdosing or inefficient regimen. Simulation can also be 
used to quickly disqualify drugs which would likely prove to be ineffective. And lastly, 
when therapeutics prove effective in an individual patient, the effectiveness might only 
be marginal, and the cancer can rapidly develop resistance. NLME modeling can be 
used to optimize therapies on an individual level, increasing base effectiveness and 
reducing the necessary timespan of treatment; the longer treatment persists, the more 
likely the cancer develops resistance to the treatment (6). 
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The basic structure underlying most pharmaceutical modeling is two-part. First, 
drugs have kinetic properties resulting from both their chemical properties and the 
biological actions of the body on the drug. The study of pharmaceutical kinetics is called 
pharmacokinetics (PK). For example, when a small polar molecule is injected 
intravenously, basic laws of thermodynamics govern the distribution of the 
pharmaceutical throughout the cardiovascular system. The body ultimately takes some 
action on that drug which effectively removes it from circulation – either degrading it, 
excreting it, or sequestering it. The stages of pharmacokinetics are absorption, 
distribution, metabolism, and elimination. The second concept underlying most 
pharmaceutical modeling is pharmacodynamics (PD). Drugs have actions on the bodies 
of patients resulting in predictable dynamics, usually by interaction with cellular 
receptors or intercellular signals. For example, bevacizumab binds to and disables 
vascular endothelial growth factor (VEGF). VEGF is a cellular signaling medium which 
communicates the need for new vasculature (i.e. hypoxia). When VEGF signaling is 
attenuated, vascular growth is limited. The studies presented in this dissertation 
invariably use NLME models with this two-part (PKPD) structure to solve problems in 
modeling and simulation of therapeutics (6). 
In the first publication presented in this dissertation, my coauthors and I outline 
the philosophical framework that we have used to solve research problems in PKPD 
modeling using population models. The traditional experimental paradigm for 
developing pharmaceuticals in humans requires first to induce a coarse reproduction of 
the disease in mice and then to treat the mice with a broad range of dosages to 
determine if there is therapeutic potential i.e. symptom reduction. Then, simple 
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allometric scaling is used to estimate effective human dosages. However, the rodent 
model has several broad limitations when modeling disease. Some brief examples: the 
human body is much larger than the rodent body (so the pharmacokinetics are largely 
incomparable), rodents do not spontaneously develop the majority of human diseases 
so they must be artificially induced, and clinical lab values differ significantly between 
rodents and humans. We propose several modifications to the traditional paradigm. 
Creating parallel NLME models of the animal model pathology and human pathology 
better accounts for biological differences between the animal model and humans. 
Ideally, the animal model used in therapeutic development is of spontaneously 
developed disease mirrored between the human and the animal model e.g. type I 
diabetes is a disease common in both humans and in cats. If the disease is shared 
between humans and the animal model, the number of assumptions made when 
translating results from the animal model to humans is drastically reduced. And, the 
experiments themselves reduce needless harm as the animal models are being treated 
in a veterinary clinic – rather than tested bench-side. In this setting, therapeutics can be 
jointly developed to both solve problems in human and veterinary medicine. Usually, 
researchers only consider translational research, where findings in veterinary medicine 
are applied to human medicine. However, when using spontaneous animal disease as a 
model instead of induced disease, findings can be reverse translated i.e. findings from 
experimental pharmaceuticals being developed preclinically, as well as clinically, are 
used to support the development of pharmaceuticals for veterinary use. 
In the second publication, we detail a pharmacokinetics experiment in high-dose 
pharmacological ascorbate. Several human clinical trials are currently evaluating the 
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potential cytotoxic properties of pharmacological ascorbate for NSCLC. By evaluating 
the pharmacokinetics in dogs, we have built a mathematical model that can be 
translated to human patients. We found that pharmacological ascorbate is both 
preferentially cytotoxic to in vitro canine cancer cells and can be administered at 
therapeutic levels, safely. More research must be completed to establish the validity of 
this therapeutic for canine cancer, but our findings indicate that some spontaneous 
canine cancers might in the future serve as an ideal preclinical model for their human 
analog when evaluating pharmacological ascorbate. It also opens the possibility for 
future reverse translation from human findings in pharmacological ascorbate to 
veterinary medicine. 
In the third publication, we report a preclinical experiment in bevacizumab-
pemetrexed/cisplatin combination therapy for NSCLC and the mathematical modeling 
and simulations which were developed using that experimental data. Various 
publications have suggested that administering bevacizumab at a gap of one or more 
days before pemetrexed/cisplatin enhances the efficacy of their combined use. An 
attractive feature of optimizing the scheduling of bevacizumab-pemetrexed/cisplatin is 
that dosages can potentially be reduced, improving the tolerability of the therapy. We 
used a NSCLC-xenografted mouse model to experimentally measure the improvement 
resulting from sequential bevacizumab-pemetrexed/cisplatin. In the experiment, small, 
human NSCLC tumors were xenografted onto 90 mice. The mice were randomized into 
several treatment groups in which bevacizumab was administered either concurrently, 
or sequentially at a gap of one or more days. We found a significant increase in efficacy 
when bevacizumab was administered sequentially with pemetrexed/cisplatin, rather 
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than concomitantly. We next used the data to a fit a semi-mechanistic NLME PKPD 
model of bevacizumab-pemetrexed/cisplatin against NSCLC in xenografted mice. After 
obtaining a satisfactory fit, we translated the model to humans using sparse data 
collected in a separate study. With the final clinical model, we predicted that over 85 
days, optimizing sequential bevacizumab-pemetrexed/cisplatin therapy resulted in an 
approximately 48% increase in tumor volume reduction. 
In the final manuscript presented in this dissertation, we used an expansive 
dataset collated from several clinical trials in anti-NSCLC therapies to develop a 
comprehensive model of NSCLC therapeutics. Within clinical trials and between clinical 
trials, there is significant variation in scheduling of therapeutics for patients. Our goal in 
this study was to leverage that natural variation in scheduling to explain varied 
outcomes in tumor reduction. We modeled that variation in response in terms of both 
individual variability in medication response and in terms of efficiency gained from 
optimized scheduling. Building on our previous findings, we were especially interested 
in optimizing sequential scheduling of bevacizumab with various anti-proliferatives. 
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Abstract 
There is growing concern about the limitations of rodent models with regard to 
recapitulation of human disease pathogenesis. Computational modeling of data from 
humans and animals sharing similar diseases provides an opportunity for parallel drug 
development in human and veterinary medicine. This “reverse translational” approach 
needs to be supported by continuing efforts to refine the in silico tools that allow 
extrapolation of results between species.  
Improving the Predictability of Animal Models Used in Preclinical Research 
Translational research remains the consensual model to develop candidate 
drugs into clinical therapeutics. In the translational framework, drug pharmacokinetics 
(PKs) and pharmacodynamics (PDs) are first characterized in animal models, and the 
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results of those preclinical studies are then extrapolated to humans. Currently, out of the 
few candidates that move forward to the development stage, 35% attrition in phase II 
studies are caused by failure to demonstrate clinical efficacy [1]. These high failure 
rates, combined with few relevant translational animal models in preclinical research, 
highlight the need for alternative approaches at the early stage of the research and 
development (R&D) lifecycle. One such approach is the reverse translational model. 
A well‐known application of the reverse translational paradigm consists in the 
prediction of drug side effects and/or efficacy for individual patients using specific single 
nucleotide polymorphism information. The scope of reverse translation is actually 
broader, as we see it as an opportunity to synergize the information available from 
humans and animals sharing analogous diseases to develop improved predictions and 
therapies for both human and veterinary patients (figure 3.1).  
The innovative nature of this approach, underpinned by the “One Health” 
initiative, is based on the underlying hypothesis that the use of animal models that 
spontaneously develop similar diseases to humans will improve the predictability of 
preclinical models used for biomedical research purposes. In return, quantitative PK/PD 
information gathered from human clinical studies present an opportunity to stimulate 
veterinary drug development, thus optimizing the utilization of existing resources and 
the application of available knowledge (i.e., from humans to animals and vice versa). 
This contrasts starkly with the common translational practice of developing genetically 
engineered animal models of disease in preclinical research. 
In reverse translational pharmacology, computational modeling of drug PK/PD 
assists in the selection of promising therapeutic candidates and the prediction of their 
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optimal dosing schedules (i.e., dose and frequency) in humans and animals. This is 
achieved through extrapolation of disposition kinetics, efficacy, and safety data from/to 
spontaneous animal models of the human disease pathophysiology to/from the clinic. 
One Health and Comparative Medicine to Support Drug R&D 
One Health is a cross‐disciplinary effort aiming to improve the assessment, 
treatment, and prevention of disease in people and animals [2]. An important subfield of 
One Health is comparative medicine, which offers the possibility to use spontaneous 
animal models with naturally occurring diseases for drug R&D. These animal models 
have unique experimental advantages, especially over the mouse, which may provide 
insight into previously intractable diseases. In particular, many human disorders, 
including cancer, diabetes mellitus, chronic enteropathies (e.g., inflammatory bowel 
diseases (IBD)), hypertension, and congestive heart failure have well‐studied clinical 
analogs in dogs (supplementary table 3.S1). Domesticated animals also share several 
environmental risk factors with humans, simplifying experimental controls. In addition, 
biological relevance of genomic data can be supported by identifying human‐animal 
genetic homologs, as is the case in IBD, in which the importance of genetic 
susceptibility in disease development has been established in both species. Below, we 
highlight three examples of diseases in which reverse translational modeling have been 
used to support pharmaceutical research.  
Cancer Research 
About 6 million dogs are diagnosed with cancer each year, and >50% of dogs of 
10 years or more will develop cancers, such as lymphoma, osteosarcoma, and 
melanoma [3]. Although murine models have been extremely useful for studying the 
biology of cancer development, mice usually do not adequately represent many of the 
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features constitutive of human cancers, including genomic instability and tumor 
heterogeneity [4]. In dogs, cancers develop naturally within a syngeneic host and tumor 
microenvironment, and in the context of an intact immunity. Dogs and human cancers 
share similar features, such as background genetics, histological appearance, 
therapeutic response, and acquired resistance [4]. One good example of the use of 
canine models to support cancer therapy pertains to the development of the 
inflammatory cytokine interleukin (IL)‐12 as a potential treatment for malignant 
melanoma. The use of cytokines to enhance antitumor immunity has been recognized 
as an important immunomodulatory approach in cancer management. Yet, historically, 
the high risk for systemic toxicity presented by IL‐12 dosing has prevented development 
of this cytokine into a therapeutic. A strong genetic similarity exists between canine and 
human IL‐12 (i.e., 84% homology for the ligand and 68% homology for the receptor), 
whereas dogs develop spontaneous malignant melanoma with similar biology to human 
tumors. These analogies provided impetus for the characterization of IL‐12 PK/PD, 
efficacy, and toxicity in canine clinical trials [5]. Results from the dog study showed that 
high levels of IL‐12 could be safely administered subcutaneously to patients with 
malignant melanoma, while maintaining both systemic immunological and clinical 
activity. This was demonstrated by measuring serum IL‐12 and other representative 
biomarkers (e.g., IL‐10) over time, and establishing PK/PD models of IL‐12. These 
findings in dogs were key to guide the sponsor's decision to move forward with a phase 
I clinical trial in humans. In turn, preliminary studies focusing on IL‐12 gene 
electrotransfer in dog patients with melanoma have shown promising results for the 
treatment of spontaneous canine tumors [6]. 
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Inflammatory Bowel Disease 
IBD is a highly prevalent disorder in both humans and dogs. Importantly, dogs 
with IBD exhibit similar clinical symptoms, show involvement of the same cells, 
inflammatory genes and molecular pathways, and have a time course of disease 
progression similar to humans. In fact, a copious amount of literature has established 
that human and canine IBD have common clinical and molecular features, such that 
clinical trials in dogs with IBD are particularly relevant to study the efficacy and safety of 
candidate drugs intended for use in humans [7]. In a recent collaboration between the 
Iowa State University and the University of Navarra, IBD was modeled using a network 
systems approach based on Boolean equations [8]. The model was used to simulate 
the effect of a noncompetitive antagonist of the purinergic receptor P2X7 and guide 
dose selection for an upcoming clinical study in IBD in dogs. The model used 
inflammatory biomarkers IL‐1β and IL‐18 as well as the tissue damage biomarkers 
matrix metalloproteinases as surrogate end points of efficacy. Assuming that matrix 
metalloproteinases levels are associated with clinical disease activity, results from the 
simulations showed that the selected dose of the drug candidate should antagonize at 
least 75% of the target receptor. These findings will now inform the design of a proof‐of‐
concept study in IBD dogs prior to clinical development in humans. 
Congestive Heart Failure 
Another therapeutic indication in which modeling efforts have been made to 
better characterize the effects of drugs in naturally occurring animal models of human 
disease is congestive heart failure (CHF). In humans and dogs, CHF is often synergistic 
with renin angiotensin aldosterone system (RAAS) overactivation. This is due to the 
excessive release of renin from the juxtaglomerular apparatus, a well‐described 
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compensatory mechanism to the reduced cardiac output observed in symptomatic 
stages of CHF. Although there is no mathematical description of the PK/PD of 
angiotensin‐converting enzyme (ACE) inhibitors in spontaneous cases of canine CHF, 
the kinetics and effects of benazeprilat have been characterized in a low‐salt diet model 
of RAAS activation [9]. Similar to humans, ACE inhibitors are commonly dosed in the 
morning in dogs. However, using a nonlinear mixed‐effect model to describe the 
dynamics of RAAS biomarkers in dogs, Mochel et al [9] have shown that the timing of 
food intake exerts a synchronizing effect on the RAAS, such that dosing with ACE 
inhibitors should be adjusted according to the time of food intake. Using a mechanism‐
based PK/PD model, the authors further established that ACE activity alone was not a 
predictive marker of RAAS activity in dogs because, as reported in humans, 
benazeprilat exerts a moderate effect on angiotensin II and aldosterone, despite a 
complete and long‐lasting inhibition of ACE. 
Opening the “Black Box” of Complex Biological Networks 
The reductionist approach to biomedical research has been successful in 
identifying key mechanisms contributing to disease modulation. However, it has become 
increasingly apparent that a more integrated approach is required to characterize the 
pathophysiology of complex biological systems. This was nicely illustrated with the IBD 
example above for which a systems pharmacology model comprised of 43 nodes and 
298 interactions was developed by combining human and animal data on a large 
number of cytokines, immune cells, and proteins to predict the therapeutic efficacy of 
prospective candidate drugs. As high‐throughput sequencing and metabolomics 
techniques continue to improve, this mechanistic model could be expanded further to 
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decipher the mechanisms by which diet and genetic backgrounds impact disease 
susceptibility [10]. 
Conclusion 
Reverse translational pharmacology is an expanding field of research with the 
promise to improve existing preclinical models for better characterizing the efficacy and 
safety of candidate drugs and, ultimately, selecting the most promising therapeutics 
intended for use in humans. In return, from the perspective of developing veterinary 
pharmaceuticals for spontaneous diseases in animals, reverse translational 
pharmacology also presents an opportunity to leverage information from PK and PD 
studies in humans for the benefit of veterinary medicine. The success of the reverse 
translational paradigm relies on more systematic interdisciplinary research and cross 
talks among physicians, veterinarians, and quantitative scientists. To achieve this, the 
Comparative Oncology Program of the National Cancer Institute has established a 
multicenter collaborative network of 22 veterinary academic partners known as the 
Comparative Oncology Trials Consortium. The mission of the Comparative Oncology 
Trials Consortium is to answer biological questions geared to inform the development 
path of chemotherapeutics for future use in human patients with cancer. Additional 
initiatives from the National Institute of Health include several multimillion‐dollar funding 
opportunities to foster collaborative programs for multidisciplinary teams (e.g., PAR‐17–
340 and RFA‐CA‐17‐002). Active participation of industrial partners is also key to the 
success of reverse translational research. This was exemplified by the 5‐year 
Cooperative Research and Development Agreement between the US Food and Drug 
Administration Center of Veterinary Medicine and Certara (www.certara.com) aiming to 
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deliver physiologically based PK dog models and assesses the impact of polymorphic 
variations on interspecies extrapolation. Regulatory incentives to develop parallel 
(veterinary and human) drug development programs could present an opportunity to 
encourage such collaborations in the future. 
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Tables and Figures  
Table 2.S1 Examples of Diseases that Have Clinical Analogs in Dogs  
References can be accessed online using; Riviere et al., 2017 J Vet Pharmacol Ther 
18(4): 347-360. 
Cancer 
Lymphoma Ito D et al., Vet Immunol Immunopathol. 2014 Jun 15;159(3-4):192-
201 
Melanoma Atherton MJ et al., Vet Immunol Immunopathol. 2016 Jan;169:15-26 
Osteosarcoma Roy J et al., PLoS One. 2017 Sep 14;12(9):e0183930 
Colorectal Cancer Colorectal Cancer 
Gastrointestinal Stromal Tumors Gregory-Bryson E et. al., BMC Cancer. 2010 Oct 15;10:559 
 
Cardiovascular Diseases 
Congestive Heart Failure Haidara MA et al., Curr Vasc Pharmacol. 2015;13(5):658-69 
Metabolic Syndrome Montoya-Alonso JA et al., Front Vet Sci. 2017 Apr 25;4:59 
Chronic Kidney Disease Martinez-Hernández L et al., Vet J. 2017 Mar;221:1-5 





Table 2.S1 Continued 
Gastrointestinal Diseases 
Inflammatory Bowel Disease Jergens AE et al., Front Biosci (Elite Ed). 2012 Jan 1;4:1404-19. 
Idiopathic Chronic Hepatitis Bexfield N, Vet Clin North Am Small Anim Pract. 2017 
May;47(3):645-663 
Pancreatitis Waltson P, J Small Anim Pract. 2015 Jan;56(1):3-12 
Gastrointestinal Ulcers Fitzgerald E, et al., J Small Anim Pract. 2017 Apr;58(4):211-218 
 
Endocrine Disorders 
Type 1 Diabetes O'Kell AL, et al., Sci Rep. 2017 Aug 25;7(1):9467 
Addison's Disease Hanson JM, et al., J Vet Intern Med. 2016 Jan-Feb;30(1):76-84 







Schütt T, et al., J Alzheimers Dis. 2016 Mar 15;52(2):433-49 
Epilepsy Marios Charalambous, etl al., BMC Vet Res. 2014; 10: 257 
Polyneuropathy Vitale CL, Olby NJ, J Vet Intern Med. 2007 Nov-Dec;21(6) 
Meningoencephalitis Uchida K, et al. Vet J. 2016 Jul;213:72-7 
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Figure 2.1 Translational vs. Reverse Translational Sciences  
Reverse translational sciences is a bidirectional approach in which clinical findings from 
patients are used to design early studies in relevant animal models of (spontaneous) 
disease. The information generated in animal studies will later be used to predict the 
efficacy and safety of future therapeutics in human clinical trials. 
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Abstract 
High-dose, pharmacological ascorbate (P-AscH−) is preferentially cytotoxic to 
human cancer cells in vitro. Investigations on the efficacy of P-AscH− as an adjuvant 
treatment for multiple human cancers are on-going, but has yet to be formally 
investigated in dogs. The primary objectives of this study were to determine the 
pharmacokinetic (PK) profile of P-AscH− in healthy Beagle dogs and the effects of P-
AscH− on canine osteosarcoma cells in vitro. 
In pursuit of these ends, eight purpose-bred, healthy, spayed female Beagle 
dogs, between 20 and 21 months old, and 8–10 kg were administered two doses of P-
AscH− (550 or 2,200 mg/kg) via intravenous infusion over 6 h, on separate days. 
Plasma ascorbate concentrations were measured at 12 time points during and after 
infusion for PK analysis using nonlinear mixed-effects (NLME) and non-compartmental 
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analysis (NCA). Clonogenic assays were performed on 2 canine osteosarcoma cell 
lines (D-17 and OSCA-8) and canine primary dermal fibroblasts after exposure to high 
concentrations of ascorbate (75 pmoles/cell). 
 
Plasma ascorbate levels in the dogs peaked at approximately 10 mM following 
2,200 mg/kg and returned to baseline 6–8 h after dosing. Minor adverse effects were 
seen in two dogs. Ascorbate (75 pmoles/cell) significantly decreased survival in both the 
osteosarcoma cell lines (D-17 63% SD 0.010, P = 0.005; OSCA-8 50% SD 0.086, P = 
0.026), compared to normal fibroblasts (27% SD 0.056). 
From these results, we have concluded that pharmacological ascorbate is 
preferentially cytotoxic to canine-derived cancer cells, and high levels of ascorbate can 
be safely administered to dogs. Further studies are needed to determine the effects of 
P-AscH− on canine patients. 
Introduction 
The potential benefit of high-dose intravenous (IV) pharmacological ascorbate 
(P-AscH−, vitamin C) for patients with cancer was first reported in the 1970s [1,2]. 
Subsequent clinical trials failed to show substantial improvement in outcome [3], stalling 
its clinical use [4]. However, P-AscH− continued to be a popular alternative cancer 
therapy [5,6]. The potential anti-cancer properties of P-AscH− are being reevaluated. 
Several human clinical trials are examining the efficacy and safety of P-AscH−, for 
example in non-small cell lung carcinoma (NSCLC) [7], glioblastoma multiforme (GBM) 
[7], and pancreatic cancer [8,9], indicating renewed interest in the therapeutic use of P-
AscH− for human cancer patients. 
22 
Ascorbic acid is a weak acid with pKa1 of about 4.2 [8]. Thus, at the near-neutral 
pH of mammalian biology, greater than 99.9% will be present as the monoanion, i.e., 
ascorbate. The biochemistry for the functions of vitamin C is principally the biochemistry 
of ascorbate. In this work, we use the term pharmacological ascorbate, P-AscH−, to 
distinguish the functioning of ascorbate as a drug from its biochemistry as vitamin C 
[10,11]. When at normal, healthy physiologic levels ascorbate functions as a reducing 
agent and donor antioxidant [12]; however, at supraphysiological concentrations, P-
AscH− can produce high fluxes of H2O2 via its oxidation [8,9,13]. The cytotoxic 
mechanism of P-AscH− appears to be due to these fluxes of H2O2 and, in part, to 
alterations in cancer cell oxidative metabolism, allowing for increased steady-state 
levels of O2
∙− and H2O2 within tumor cells [7,14,15]. These alterations disrupt intracellular 
iron metabolism, sensitizing cells to the effects of the oxidation of P-AscH− [7,14,15]. 
Multiple in vitro studies have confirmed the cytotoxic effects of P-AscH− on human and 
murine tumor cells, and the sparing effect on normal cells [10,11,14,15]. 
Human studies of P-AscH− have determined that therapeutic, cytotoxic plasma 
levels (≥≈20 mM) cannot be achieved through oral administration (PO) [16]. Therefore, 
IV or intraperitoneal (IP) injection is required [16,17]. In addition, high-dose IV P-AscH− 
infusions (15–125 g), given over hours, are required to achieve and maintain proposed 
therapeutic plasma levels due to the rapid clearance of ascorbate [7,16–19]. The 
optimal dose of P-AscH−, frequency, and duration of administration have yet to be 
determined [20]. 
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Pharmacological ascorbate is generally well-tolerated and appears to have no 
dose-limiting toxicities in humans [6]. Adverse effects that have been described include 
vomiting, diarrhea, weight loss, leukopenia, and neutropenia [6,7,10,21]. 
Canine pharmacokinetic (PK) analysis of PO ascorbate, but not P-AscH−, has 
been scientifically evaluated [22]. In 4 Greyhounds that were treated with 1 g of 
ascorbate PO or IV, peak ascorbate plasma concentrations were significantly greater 
when ascorbate was administered IV (mean 0.33 ± 0.06 mM) compared to PO (mean 
0.03 ± 0.01 mM) and was achieved within 6 min, falling rapidly back to baseline (mean 
0.01 mM) within 6 h [23]. Recently, seven dogs were reported to have received various 
doses of IV ascorbate for the adjuvant treatment of multiple cancers with minimal side 
effects [24]. Data regarding the PK of P-AscH− in dogs, and if P-AscH− would be a 
feasible treatment option for our canine patients, are lacking. 
The purpose of this study was two-fold: (1) determine the PK profile of P-AscH− 
in healthy Beagle dogs; and (2) determine the effects of P-AscH− on canine 
osteosarcoma cells. Given the lack of significant adverse side effects reported in 
humans, we hypothesized that IV P-AscH− would be safe for use in dogs and that in 
vitro, P-AscH− would cause significant cytotoxicity to canine osteosarcoma cells. The 
PK data presented here can guide the development of treatment protocols that are 
feasible for use in the veterinary clinical setting. 
Methods 
Experimental Animals 
Eight purpose-bred, spayed female Beagles, between 20 and 21 months old, and 
8–10 kg were used in this study. The dogs were obtained from Ridglan Farms, Mt. 
Horeb, WI. The use of the Beagles for this study was approved by the Iowa State 
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University Institutional Animal Care and Use Committee. Compliance with the US 
National Research Council's Guide for the Care and Use of Laboratory Animals was 
maintained throughout the study. The Beagle dogs were group-housed in the same 
conditions and fed the same Royal Canin® diet for the duration of the study. Prior to 
infusions of P-AscH− and collection of blood samples, dogs were fasted overnight with 
free choice water available at all times. 
Ascorbate Administration 
Two doses of injectable L-ascorbic acid, 500 mg/mL (Mylan Institutional LLC, 
Canonsburg, PA), were administered on two separate days. (Although labeled as 
Ascorbic Acid for Injection, the contents are at near-neutral pH, thus vials contain 
ascorbate.) A low dose (550 mg/kg) was administered on the first trial day. This dose 
was escalated to 2,200 mg/kg for administration on the second trial day, as previously 
reported [24]. At least a two-day washout period was given between each dose. 
Administration of ascorbate was performed through a 20 gauge, peripheral short IV 
catheter in the left or right cephalic vein of each dog. Pharmacological ascorbate was 
combined with sterile water to achieve a 500 mg ascorbate per mL solution with a 
targeted osmolarity between 500 and 900 mOsm/L [7]. The infusion was given over 6 h 
(12.5 mL/h for the 550 mg/kg dose; 50 mL/h for the 2,200 mg/kg dose) via an IV 
infusion pump in order to achieve a steady-state plasma ascorbate concentration. Dogs 
were continuously monitored during the infusion and intermittently for 24 h post infusion 
for adverse clinical signs. 
Plasma Ascorbate Sample Preparation and Analysis 
To evaluate plasma ascorbate concentrations throughout and after infusion, 
blood was sampled at 12 time points: immediately prior to the ascorbate infusion, a 
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baseline venous sample was obtained; venous blood was sampled at 0.5, 1, 3, 5, and 6 
h during the infusion period; and at 6.5, 7, 8, 10, 12, and 16 h during the post-infusion 
period. Prior to the higher dose infusion (2,200 mg/kg), and at the 6 h mark of the higher 
dose infusion, arterial samples for blood gas analysis were also obtained. All venous 
blood collection was performed via a Cavafix® (B Braun Medical Inc., Breinigsville, PA) 
sampling catheter placed in either the left or right lateral saphenous vein, to the level of 
the caudal vena cava, following manufacturer recommendations [25]. At each time 
point, 2 mL whole blood samples were drawn into a Vacutainer® PST™ Lithium Heparin 
(Becton Dickinson, Franklin Lakes, NJ) green top tube and promptly stored on ice until 
centrifugation. Blood was centrifuged for 20 min at 4°C and 2,000 rpm (671 g). Plasma 
was collected and stored at −80°C until analysis [26]. Arterial samples for blood gas 
analysis were obtained via an AirLifeTM Reduced Heparin Arterial Blood Sampler 
(CareFusion). 
Plasma ascorbate quantification was conducted at The University of Iowa using 
two different assay systems as previously described [27,28]. Briefly, a plate reader 
(SpectraMax® M3, Molecular Devices, Sunnyvale, CA) was used to measure baseline 
and physiological levels of ascorbate present in the plasma samples [28]. To quantify 
the high pharmacological levels of ascorbate a second assay using an Implen 
Nanophotometer (Implen GmbH, Munich, Germany) microvolume UV-Vis spectrometer 
was used. With little required sample processing, this assay, developed at The 
University of Iowa [27], allows rapid assessment of ascorbate concentrations in plasma 
ranging from 2.9 to 35 mM. 
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Arterial blood gas samples were processed by the Iowa State University Clinical 
Pathology Lab using a RAPIDPoint® 500 Blood Gas Analyzer (Siemens Medical 
Solutions USA, Inc., Malvern, PA). Additional complete blood counts, chemistries, and 
urinalyses were performed in conjunction with another study taking place during the 
same time period. 
Pharmacokinetic Modeling 
Time-courses for the concentration of ascorbate in blood plasma following low-
dose and high-dose IV infusion were analyzed simultaneously using the stochastic 
approximation expectation maximization (SAEM) algorithm implemented in the Monolix 
Suite 2018R2 (Lixoft, France). Data below the lower limit of quantification (LLOQ) were 
modeled by adding to the likelihood function a term describing the probability that the 
true observation lies between zero and the LLOQ. Individual model parameters were 
obtained post-hoc using the mean of the full posterior distribution, as previously 
described for nonlinear mixed-effects (NLME) models in animal health [29]. 
Convergence of the SAEM algorithm was evaluated by inspection of the stability of the 
fixed and random effect parameter search and the log-likelihood estimate after the 
exploratory period of the algorithm (i.e., after 1,000 iterations of SAEM). Standard 
goodness-of-fit diagnostics, including individual predictions vs. observations, the 
distributions of weighted residuals, and normalized prediction distribution errors were 
used to assess the performances of the candidate models [30–32]. Prediction 
distributions from 1,000 Monte Carlo simulations were used to evaluate the ability of the 
final model to reproduce the variability in the observed pharmacokinetic data. Residual 
error estimates from the mathematical models were used as supportive information for 
evaluation of lack of fit. Normality and independence of residuals were assessed using 
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histograms, quantile-quantile plots, and autocorrelation of conditional weighted 
residuals. For converging models with satisfactory goodness-of-fit diagnostics, model 
selection was based on the Bayesian information criteria (BIC) and the precision of the 
model parameter estimates. 
For completeness, non-compartmental analysis (NCA) of ascorbate PK was 
performed using PKanalix (Monolix Suite 2019R1, Lixoft, France). Standard PK 
parameters were generated for individual dogs, as follows: 
 ;Area under concentration-time curve, AUCINF ־
  A linear trapezoidal linear rule was used to estimate the area under the 
ascorbate time-curves 
 ;Maximum concentration, CMAX ־
 ;Steady state concentration, CSS ־
 ;Steady state volume, VSS ־
 ;Clearance, Cl ־
 ;Time of maximum concentration, TMAX ־
 ;Half-life, T1/2 ־
 ;Elimination rate constant, λz ־
  Computed by linear regression of the logarithmic concentration vs. time 
curve during the elimination phase 
In Vitro Ascorbate Analysis – Cell Lines and Reagents 
Two canine osteosarcoma cell lines were obtained, D-17 (American Type Culture 
Collection, Rockville, MD, USA) and OSCA-8 (Kerafast, Inc., Boston, MA), and grown in 
pyruvate free DMEM 10% fetal bovine serum (FBS). Canine primary dermal fibroblasts 
were obtained as a normal tissue control (Cell Biologics, Chicago, IL). Cell lines were 
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grown in proprietor complete fibroblast media (M2267 for dermal fibroblasts) containing 
1 mM pyruvate. Cells were kept in either 21 or 4% O2 at 37°C, 5% CO2, in a humidified 
atmosphere. 
For cell culture studies, ascorbate stock solutions, 1 M in water, with the pH 
adjusted to 7.0 with NaOH were prepared from L-ascorbic acid (Macron Fine 
Chemicals, Avantor Performance Materials, Inc., Center Valley, PA) and stored in the 
dark at 5°C in sealed glass test tubes until use [11]. The ascorbate stock concentration 
was verified spectrophotometrically. Appropriate volumes of the stock to achieve 50 
pmole/cell (5 mM) and 75 pmol/cell (7.5 mM) were added to culture media for 1 h as 
previously described [7,11]. 
In Vitro Ascorbate Analysis – Clonogenic Survival Assay 
To determine the effect of P-AscH− on the reproductive integrity, D-17 and 
OSCA-8 canine osteosarcoma cells were plated at 80,000 cells per 60-mm dish. 
Seventy-two hours after plating, one dish was counted to determine the number of cells 
on the plate. The volume of media in the dishes was adjusted so that cells were treated 
with a range of stock ascorbate, 2.5 pmoles/cell (0.25 mM)−50 pmoles/cell (5 mM). 
Ascorbate was dosed per cell as previous literature has demonstrated that H2O2 and 
ascorbate toxicity depends on cell number/density [15,33,34]. After 1 h of P-
AscH− treatment both floating and attached cells from control and treated dishes were 
collected using 0.25% trypsin (GIBCO). Trypsin was inactivated with media containing 
any floating cells, centrifuged at 1,200 rpm (335 g) for 5 min and resuspended in fresh 
media. Cell counts were made with a Coulter Counter (Beckman Coulter Z1) and the 
cells were plated at various densities and allowed to grow for 10–12 days in complete 
media at 21% O2. Subsequently, the cells were stained with Coomassie Blue dye, and 
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colonies of >50 cells on each plate were counted and recorded. Surviving fraction was 
determined as the number of colonies per plate divided by the number of cells initially 
added to that plate. Normalized surviving fraction was determined as the surviving 
fraction of any given clonogenic plate from a treatment group divided by the average 
surviving fraction of the control (untreated) plates within a given experiment. 
The clonogenic experiment comparing osteosarcoma cells to canine fibroblast 
cells were performed similarly with the following exceptions. Optimal conditions for 
normal fibroblasts is 4% O2 (normal physiologic condition) and proprietary media 
(complete fibroblast media M2267) which contains sodium pyruvate, known to scavenge 
H2O2 [15]. In addition, normal canine fibroblasts will only form clones when plated on 
lethally irradiated feeder cells (see below). Therefore, in experiments comparing the 
reproductive viability of P-AscH− on cancer cells vs. fibroblasts, the dose of P-
AscH− was increased to 75 pmol/cell (7.5 mM) and all cultures, including the sarcoma 
lines, were treated in identical fibroblast media at 4% O2 and plated onto feeder cells. 
In Vitro Ascorbate Analysis – B1 Feeder Layer Cells 
Chinese hamster fibroblasts designated as B1 (passages 20–40) were 
maintained at 21% oxygen in high glucose DMEM 1× media containing L-glutamine and 
sodium pyruvate and supplemented with 10% FBS, 20 mmol/L HEPES, pH 7.3, 1× 
MEM non-essential amino acids. The feeder layer was prepared 24 h prior to any 
clonogenic survival assay by irradiating the cells with 30 Gy of X-rays at a dose rate of 
27 Gy/min then plating in the cloning dishes at 100,000 cells per dish. During 
clonogenic survival assays comparing P-AscH− treatment of cancer cell lines to normal 
canine fibroblasts, all cloning plates were grown using a feeder layer and each 
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clonogenic experiment had two extra dishes plated with feeder cells alone to ensure no 
colony growth at the end of the 10- to 12-day incubation. 
Statistical Analysis 
The clonogenic survival analysis was done using a minimum of three cloning 
dishes per experimental condition, and the experiments were repeated a minimum of 
three times on separate occasions. Statistical analyses were done using the GraphPad 
Prism software. Statistical significance was determined using one-way ANOVA and 
Dunnett's multiple comparisons test was performed. Error bars represent ± standard 
error of the mean, and statistical significance was defined as P < 0.05. 
The Wilcoxon signed rank test was used to examine the difference between the 
pre- and post-ascorbate administration for each of nine safety parameters evaluated by 
blood gas. A P-value < 0.05 was considered significant. Statistical analysis was 




The ascorbate infusion was well-tolerated by all dogs, with one dog experiencing 
a grade I veterinary cooperative oncology group-common terminology criteria for 
adverse events (VCOG-CTCAE) vomiting during the higher dose infusion, and another 
showing VCOG-CTCAE grade I nausea/ptyalism [35]. No changes on complete blood 
count or chemistry panels were noted during the course of the study for any dog. Blood 
gas analysis revealed statistically significant changes in pre- and post-ascorbate 
calcium, sodium, potassium, chloride, bicarbonate, partial pressure of carbon dioxide, 
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anion gap, lactate, and glucose measurements (table 2.1). The pH was not significantly 
different pre- and post-ascorbate administration. 
In Vivo Pharmacokinetics 
The mean initial plasma ascorbate concentration for the eight dogs at the 550 
mg/kg P-AscH− dose (≈4 g) was 0.02 mM (± 0.01 mM). Over the course of the 6-h 
infusion, this peaked to 2.14 mM (± 0.54 mM). Once the infusion was completed, 
ascorbate levels fell sharply below therapeutic levels, and returned to near baseline by 
6 h post infusion (figure 2.1). The mean initial plasma ascorbate concentration for the 
eight dogs at the 2,200 mg/kg dose of P-AscH− (≈15–21 g) was 0.02 mM (± 0.01 mM). 
Over the course of the 6-h infusion, this peaked to 8.6 ± 2.1 mM. Once the infusion was 
completed, ascorbate levels fell sharply below proposed therapeutic levels, and 
returned to near baseline by 6 h post infusion (figure 2.1). 
A two-compartment mammillary disposition model with first-order elimination and 
zero-order absorption following IV infusion best described the PK of ascorbate in 
plasma (figure 2.2). A combined error model with an additive and a proportional error 
term was used to account for the residual noise in ascorbate measurement. The 
robustness and predictive performances of the final model were supported by the 
inspection of the standard goodness-of-fit diagnostics (supplemental figure 2.S1). 
Overall, the model was able to reproduce the individual experimental data for the two 
dosing schedules with excellent accuracy, as shown by the quality of the individual fits 
(figure 2.3). 
Using standard mathematical equations for a two-compartment PK model [38], 
the elimination half-life of ascorbate in canine plasma can be estimated at ~3.5 h. 
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Population PK parameter estimates and their related variances are summarized in table 
2.2. For all model parameters, the precision of the final estimates was considered 
satisfactory (RSE ≤ 25%). The systemic total body clearance (CL) of ascorbate was 
estimated to be low to moderate (2.0 L/h, or 0.24 L/kg/h), according to previous 
definition [39], while the steady-state volume of distribution was estimated to be 
relatively small (2.69 L or 0.32 L/kg), with the central compartment occupying most of 
the distribution of ascorbate in dogs. The global extraction ratio of ascorbate (E) 
calculated as CL/Q [with cardiac output Q (mL/kg/min)] approximated by the formula: Q 
= 180 × BW−0.19 [39], was estimated to be low (E = 0.03). 
Prediction distributions (from the 2.5th to 97.5th percentile) derived from 1,000 
Monte Carlo simulations confirmed the good performances of the final selected model 
which was able to reproduce the variability in the observed disposition kinetic data of 
circulating ascorbate following IV infusion dosing (figure 2.4). 
The NCA PK parameters are collated in table 2.3. The mean maximum 
ascorbate plasma concentration was estimated as 9.23 ± 1.33 mM for beagles 
administered 2,200 mg/kg P-AscH− and 2.26 ± 0.61 mM for beagles administered 550 
mg/kg P-AscH−. Peak plasma concentrations were observed around a median value of 
5.5 ± 1.0 h. Mean clearance and steady state volume estimates were unremarkable 
(2.05 ± 0.35 L/h and 3.52 ± 1.54 L respectively). The median elimination half-life was 
estimated at 3.73 ± 1.47 h. All NCA PK parameters agree well with their NLME 
counterparts. 
Clonogenic Assay 
To test the hypothesis that treatment with P-AscH− decreases clonogenic survival in 
canine osteosarcoma cancer cells, D-17 and OSCA-8 were treated with 0.25–50 
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pmol/cell ascorbate for 1 h. In both cell lines, P-AscH− treatment resulted in significant 
(P < 0.001), dose-dependent decreases in clonogenic cell survival compared to 
untreated controls (figure 2.5, A). To test the hypothesis that P-AscH− causes 
differential susceptibility in osteosarcoma cells vs. normal canine dermal fibroblast, 
again clonogenic survival assay was performed. Optimal growing conditions for dermal 
fibroblast include proprietary media containing 1 mmol pyruvate and 4% O2. Both 
O2 and pyruvate have been demonstrated to affect the production and removal of 
H2O2 with ascorbate treatment [15], therefore clonogenic assay was done using 75 
pmol/cell P-AscH− for 1 h and optimal fibroblast growing conditions for both the cancer 
cell lines and normal fibroblast cells. Treatment with P-AscH− demonstrated significant 
differential susceptibility in osteosarcoma cells vs. normal fibroblast by decreasing 
clonogenic survival in both osteosarcoma cell lines (D-17 63%, SD = 0.010, P = 0.005; 
OSCA-8 50%, SD = 0.086, P = 0.026), more than normal fibroblasts (27%, SD = 0.056) 
(figure 2.5, B). 
Discussion 
Based on the plasma ascorbate concentration analysis reported herein, it has 
been determined that it is safe to administer P-AscH− (2,200 mg/kg) to healthy dogs. 
Using an infusion rate of 50 mL/h of a solution containing 500 mg ascorbate per mL, in 
vivo peak plasma ascorbate concentrations reached up to 10 mM and were found to be 
dose-dependent. To our knowledge, this is the first comprehensive characterization of 
ascorbate PK in dogs. A two-compartmental mammillary disposition model with first-
order elimination and zero-order absorption after IV infusion dosing best described the 
available PK data. Parameter estimates of the final NLME model suggest that ascorbate 
has a rather low extraction ratio (0.03) but a small volume of distribution, resulting in a 
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short elimination half-life in dogs, in agreement with previous findings from the human 
literature [19]. 
Adverse effects that were previously noted in human studies, including vomiting, 
diarrhea, and weight loss, were minimal in our canine subjects [21]. During the infusion 
of both doses, and for at least 24 h post infusion, only one dog vomited. All dogs 
remained bright, alert, and responsive, had a good appetite following the infusion, and 
maintained their body condition. This suggests that P-AscH− will be well-tolerated in 
healthy dogs, even at elevated doses. 
It is worth noting that in the present study, mild changes on blood gas analysis 
were noted after administration of 2,200 mg/kg P-AscH− (table 2.1). There are several 
possible explanations for these findings, the first of which is analytical interference. A 
significant elevation in anion gap and hyperlactatemia were observed 6 h into the 
infusion of the higher dose P-AscH− (2,200 mg/kg) in all eight dogs. Ascorbic acid has 
been shown to interfere with blood gas electrodes that use oxidase for amperometric 
methods of detection (namely lactate and glucose) [40,41], including the Siemens 
analyzer used in this study [42]. Additionally, when a comparable solution of ascorbate 
and sterile water was run alone, elevations in lactate were detected (table 2.1), 
suggesting the apparent hyperlactatemia is most likely due to an electrode analytical 
interference and may not be clinically relevant. 
Alternatively, hyperlactatemia is a reported side effect of multiple drugs, the 
mechanism of which is varied but does include interference with the Cori cycle, 
inhibition of mitochondrial protein synthesis, inhibition of the electron transport chain 
(ETC), and uncoupling of oxidative phosphorylation [43]. Recent research with P-
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AscH− in humans revealed that several of the mitochondrial ETC complexes may be 
inhibited during treatment [7], possibly contributing to the hyperlactatemia. The true 
cause of the hyperlactaemia in the Beagles is unknown and may be a combination of 
analytical interference and more insidious causes. Awareness of this possible elevation 
is extremely important as use of ascorbate becomes prevalent in clinically ill dogs and 
humans. Future studies are needed to determine if hyperlactatemia is truly due to 
analytical interference or if it might be more clinically relevant. 
Elevated bicarbonate and hypernatremia were noted and expected, as the 
formulation of P-AscH− is buffered by sodium and bicarbonate. Expected compensatory 
hypochloremia and high pCO2 were also observed. The elevation of sodium and 
decreased chloride may also be attributed to analytical inference, as erroneous 
hypernatremia and hypochloremia have been noted previously following the use of P-
AscH− [40]. Glucose, although expected to be high [44], was found to be decreased in 
all 8 Beagles. This was attributed to the fast prior to and during the infusion of P-AscH−. 
Hypokalemia was likely due to increased diffusion of ascorbate into cells, 
followed by secondary increase in Na/K-ATPase activity and rapid intracellular 
potassium uptake (dogs synthesize ascorbate from glucose via the glucuronic pathway 
and absorb it via passive diffusion, while in people ascorbate requires facilitated 
diffusion or active transport) [45,46]. This is contrary to an expected hyperkalemia that 
has been noted in humans and has been attributed to an analytical interference [40]. 
This discrepancy may be attributed to the different mechanisms by which ascorbate is 
taken into cells in dogs compared to humans. 
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Calcium at the upper end of the reference interval post-treatment was an 
unexpected finding, as in people ascorbate acts as a weak calcium chelator, possibly 
leading to hypocalcemia [47]. However, ascorbate has been shown to interfere with 
calcium analysis, much like lactate, usually resulting in false elevations [40], which may 
have occurred in our study. In addition, high doses of oral ascorbate have previously 
been found to cause hypercalcemia in broiler chickens and hens, likely due to altered 
calcium metabolism (either enhancement of intestinal absorption or resorption of bone) 
[48], which may be a phenomenon unique to species that can synthesize ascorbate, 
such as dogs. 
Most of the blood gas analysis changes, although mathematically significant, 
were considered to be mild and are likely due to analytical interference caused by high 
concentrations of ascorbate in the plasma. Knowledge of these possible alterations, 
however, are important so that overzealous correction of these temporary, and likely 
clinically insignificant, changes does not occur to the detriment of the patient. Further 
analysis is necessary to make conclusions about the causes of these observed 
changes. 
The two assays for the determination of plasma ascorbate concentrations used in 
this study have not previously been reported in a canine trial setting. The plate reader 
assay has been validated with canine, porcine and human plasma [28]. The 0 h results 
(≈20 μM) from this study fall within the established detection range for the assay and 
correspond with values that were found in the validation study [28]. To date, the Implen 
Nanophotometer has not been used to quantify plasma ascorbate in canines [49]. A 
recent study confirmed the ability to use UV spectroscopy to rapidly quantify high 
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concentrations (up to 35 mM) of human plasma ascorbate, with minimal processing 
[27]. Using this same assay on our canine plasma samples detected ascorbate 
concentrations that corresponded with those found in human and murine studies 
[7,17,21]. The novel use of these quantification methods in this study provides proof of 
concept for future studies. 
In vitro, following treatment with P-AscH− ranging from 0.25 to 50 pmole/cell, the 
clonogenic cell survival of both OSA cell lines (D-17 and OSCA-8) was significantly 
decreased compared to untreated controls in a dose-dependent manner (figure 2.5, A). 
Similarly, the clonogenic survival of both cell lines after treatment with 75 pmole/cell (7.5 
mM) of P-AscH− was significantly decreased compared to normal canine fibroblasts 
(figure 2.5, B). This is similar to human OSA in vitro studies, which showed a dose-
dependent decrease in cell growth following exposure to P-AscH− (range of doses up to 
1 mM) and a sparing of normal control cells; the most significant growth effects were 
found at the 1 mM concentration [50,51]. Similar findings have been confirmed for a 
variety of human tumors [7]. Recently, the in vitro effects of P-AscH− on canine 
melanoma cell lines have also been investigated, and show similar, dose-dependent 
findings with IC50 values (those that reduce the survival of each cell line by 50%) 
between 3.6 and 9.9 mM [52]. 
Utilizing human cell lines, ascorbate concentrations of 1–7 mM are required for 
cytotoxicity and additional cell kill is achieved with higher doses [10]. However, the 
suggested target level of plasma ascorbate that is believed to be most effective for 
humans is ≈20 mM [7]. When the Beagles received a dose of 2,200 mg/kg over 6 h, 
plasma levels peaked at approximately 10 mM around the 6 h mark. Although this is 
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above the in vitro cytotoxic threshold of 7.5 mM, it is below the target dose in humans. 
However, it is not known if the human target level of 20 mM is required, or if lower 
plasma concentrations may be equally successful. In addition, in vitro data cannot be 
directly correlated with an expected cytotoxic dose in vivo, as conditions in these two 
situations are different [15]. Specifically, for in vitro P-AscH− treatment, the cell cultures 
contain 1 mM of pyruvate which is known to remove cytotoxic H2O2, potentially 
interfering with the main mechanism of action of P-AscH−, and decreasing the observed 
effects of P-AscH− in vitro [53]. 
The level of intracellular labile iron also influences the cytotoxicity of P-
AscH− [7,14]. In general, normal cells have a lower labile iron pool compared to 
cancerous cells, potentially explaining the sparing effects of P-AscH− on normal cells. 
The level of labile iron in the OSA cells is unknown, but it is possible that they have a 
relatively decreased amount of iron, impacting the cytotoxicity of P-AscH− in vitro. 
Similarly, this would impact cytotoxic levels in vivo should a particular patient have a 
tumor with inherently less labile iron, be anemic [54], have endogenous or exogenous 
exposure to glucocorticoids [55], or have circadian drops in iron [56], complicating 
administration and assessment of an expected cytotoxic dose. In vivo tumor analysis of 
P-AscH− levels are required to fully assess the concentrations of P-AscH− achievable 
and if these levels are clinically effective. 
In vitro analysis also fails to replicate the in vivo microenvironment that exerts a 
significant influence on the achievable intracellular levels of therapeutics. Thus, direct 
correlations between the cytotoxic in vitro dose of P-AscH− and that which will be 
cytotoxic in vivo is not possible. The in vitro information can guide in vivo experiments 
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and the interpretation of results. Our in vitro data suggest that P-AscH− is cytotoxic to 
canine OSA cell lines, providing proof of concept for additional investigations in tumor-
bearing dogs. 
Interestingly, it has been determined that pancreatic cancer, NSCLC, and GBM 
cells treated with ascorbate are more sensitive to concurrent or subsequent treatment 
with ionizing radiation and chemotherapy, while normal cells were spared [7,57]. In a 
murine model, it has been shown that pharmacologic ascorbate enhances pancreatic 
tumor cell radiation cytotoxicity while offering potential protection from radiation damage 
to normal surrounding tissue [57]. This indicates that adjuvant ascorbate combined with 
other cancer therapies, may be more advantageous than ascorbate alone, or that 
synergism between treatments may imply a lower dose of P-AscH− would still be 
effective [58]. Further research into this area is needed to determine the best use of 
ascorbate in our canine patients. 
The most advantageous dosing strategy for P-AscH− is also unknown [20]. 
Recent literature report that the clearance of P-AscH− in humans following a 60-g dose 
was 6.0 L/h [19]. In light of this fast elimination from the body, a bolus loading dose 
followed by a maintenance infusion of P-AscH− was recommended to maintain P-
AscH− concentrations in the potential cytotoxic range (>20 mM) [19], but this dosing was 
not studied further. In the current Beagle study, a clearance of 2.0 L/h was identified. 
This slower clearance may indicate that an in vivo cytotoxic dose is achievable in dogs. 
This study evaluated the use of P-AscH− in healthy Beagle dogs. It is 
acknowledged that oncology patients may have significantly different plasma 
dispositions of P-AscH− due to their disease that may influence dosing, PK parameters, 
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toxicity, and efficacy of this treatment in the clinical setting. Clinical patients will be of a 
variety of breeds, who may process P-AscH− differently from Beagles due to genetic 
differences. In addition, clinical patients will be on a variety of medications, including 
chemotherapy, which may cause unintended drug-drug interactions, or alter the PK 
parameters, toxicity, and efficacy of P-AscH−. Additional studies in tumor-bearing dogs 
are needed to fully evaluate the PK parameters and impact of P-AscH− in canine 
oncology patients. 
In summary, the findings presented here give a biological basis for the efficacy of 
ascorbate in vitro and an understanding of the pharmacokinetics of P-AscH− in healthy 
dogs. Together, they provide compelling evidence to investigate the concurrent use of 
ascorbate with standard of care chemotherapy and radiation therapy in tumor-bearing 
dogs. The combined in vitro and in vivo results suggest that P-AscH− may be a safe, 
reasonable adjuvant therapeutic option for dogs diagnosed with cancer, specifically 
osteosarcoma, and that cytotoxic doses of ascorbate may be achievable in vivo. Further 
studies are necessary to determine the optimal dose to achieve cytotoxic levels in tumor 
tissue, ideal dosing strategies, and to confirm the safety profile when combined with 
traditional oncologic therapies. 
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Tables and Figures 
Table 3.1 Arterial Blood Gas and Electrolyte Abnormalities Observed in 8 Beagle Dogs 
After Receiving Pharmacological Ascorbate (2200 mg/kg) 
a) Blood was drawn at the 6-h mark immediately following cessation of pharmacological 
ascorbate infusion. b) IQR: interquartile range. c) P-values for differences were 
obtained from the Wilcoxon signed-rank test (significance level = .05). d) Canine Normal 
displays a generally accepted normal range for healthy dogs for each parameter for the 




Table 3.2 Model Pharmacokinetic Parameter Estimates as Determined by the 




















Ca (mmol/L) 1.37 1.40 .030 .030 .034 1.23 - 1.40 Decreased 
out of range  
Na (mmol/L) 146 152 6.00 4.25 .007 143 - 151 224x 
K (mmol/L) 3.56 3.39 - .170 .170 .015 3.60 - 4.70 < 1 
Cl (mmol/L) 114 107 - 7.00 1.50 .013 109 - 117 N/A 
HCO3 
(mmol/L) 
21.3 22.7 1.40 .900 .015 19.0 – 25.0 N/A 
pCO2 
(mmHg) 
37.1 39.9 2.80 3.15 .023 29.0 – 45.0 N/A 
Anion Gap 
(mmol/L) 
15.6 28.4 12.8 4.10 .007 12.0 – 21.0 N/A 
Lactate 
(mmol/L) 
.640 8.64 8.00 2.10 .007 .430 - 2.10 Increased 
out of range  
Glucose 
(mg/dL) 
107 51.5 - 55.5 23.0 .014 62.0 - 115 246 
pH 7.37 7.37 0.00 .040 1.00 7.34 - 7.45 N/A 
Parameter Symbol Unit Point Estimate RSE (%) IIV (%) 
Clearance CL L/h 2.04 3.18 6.86 
Central Volume V1 L 1.96 5.99 11.9 
Inter-compartmental 
Clearance 
Q L/h 0.16 15.0 - 
Peripheral Volume V2 L 0.76 24.7 46.6 
 
RSE: Relative Standard Error of the Estimate; IIV: Inter-individual Variability 
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Table 3.3 Noncompartmental Analysis Pharmacokinetic Parameters 
 
Figure 3.1 In Vivo Pharmacokinetics of Two Doses of Pharmacological Ascorbate in 
Eight Healthy Beagle Dogs 
Distribution of individual ascorbate concentrations (small open circles) are plotted 
alongside the mean ascorbate concentrations (dashed line) and standard error (bars) 
for all observations at each time point following ascorbate infusions (550 and 2,200 
mg/kg). 
 
   Median PK Parameters   
Group AUCINF CMAX CSS VSS Cl TMAX T1/2 λz 
Unit mM*h mM mM L L/h h h 1/h 
All 12.7 2.17 5.08 2.53 1.84 5.0 3.73 0.138 
2.2 g/kg 49.0 8.26 8.88 2.23 1.83 4.0 3.87 0.149 
0.55 g/kg 11.1 1.94 2.11 3.18 1.85 5.0 3.73 0.124 
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Figure 3.2 Pharmacokinetic Schematic Representation of the Two-Compartment Model 
Developed in this Study 
Ascorbate was administered intravenously (I.V.) with an infusion time denoted by tinf. 
The transfer between the two compartments is governed by intercompartmental transfer 
parameter Q, and the drug's elimination was determined by the clearance from the 
central compartment (CL). 
 
Figure 3.3 Individual Predicted Concentration of Ascorbate in Plasma 
Individual predicted curves (blue) are plotted against the individual measurements of 
ascorbate (gray circles) over time. There are two individual fits for each animal 
dependent on dose. The difference between the individual predictions and observations 
defines the residual error in the model, which is low in these cases. 
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Figure 3.4 Prediction of Ascorbate Distribution 
These figures were produced by Monte Carlo simulation from the model fit. Briefly, a 
population of 2,000 individuals were simulated. Half were virtually administered a dose 
equal to 2,200 mg/kg and the other half were administered a dose equal to 550 mg/kg. 
Then, at each time point from 0 to 16 h in steps of 0.05 h, i.e., (0, 0.05, 0.1, 0.15, 
…,15.95, 16), the quantiles of the resulting simulations were calculated and plotted 
along with observations for comparison (gray dots). 
 
Figure 3.5 Pharmacological Ascorbate Treatment Results in Selective Clonogenic Cell 
Death in Canine Osteosarcoma Cell Lines 
(A) Significant dose dependent decreases in clonogenic survival for two osteosarcoma 
cell lines (D-17 and OSCA-8) following treatment with 0.25–50 pmol/cell ascorbate at 
21% O2 DMEM no pyruvate 10% FBS media. (B) Significant survival differences 
between two osteosarcoma cell lines (D-17 and OSCA-8) vs. primary canine fibroblasts 




Figure 3.S1 Assessment of Quality of Model Fit 
Individual observations and individual predictions are plotted against each other to 
analyze the quality of model fit. Points have semi-transparent grey fill to reduce visual 
distortions due to over-plotting. The dashed cyan line is the spline best-fit for the data 
and the solid black line is the line of perfect fit (i.e. observation exactly equals 
prediction). The difference between the dashed and solid line indicates the degree to 
which the model is misspecified. Here, the misspecification is very low. Predictions are 
displayed in log10 scale to allow analysis of model fit across the full range of 
observations (min = 0.03, max = 11.64). 
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Abstract 
Bevacizumab-pemetrexed/cisplatin (BEV-PEM/CIS) is a first line therapeutic for 
advanced non-squamous non-small cell lung cancer (NSCLC). Bevacizumab 
potentiates PEM/CIS cytotoxicity by inducing transient tumor vasculature normalization. 
BEV-PEM/CIS has a narrow therapeutic window. Therefore, it is an attractive target for 
administration schedule optimization. The present study leverages our previous work on 
BEV-PEM/CIS pharmacodynamic modeling in NSCLC-bearing mice to estimate the 
optimal gap in the scheduling of sequential BEV-PEM/CIS. We predicted the optimal 
gap in BEV-PEM/CIS dosing to be 2.0 days in mice and 1.2 days in humans. Our 
simulations suggest that the efficacy loss in scheduling BEV-PEM/CIS at too great of a 
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gap is much less than the efficacy loss in scheduling BEV-PEM/CIS at too short of a 
gap.  
Introduction 
Bevacizumab-pemetrexed/cisplatin (BEV-PEM/CIS) combination therapy has 
been shown to be an effective first line and maintenance therapy for non-small cell lung 
cancer (NSCLC) in Phase II and Phase III clinical trials [1,2]. Pemetrexed inhibits 
enzymes necessary for pyrimidine and purine synthesis – primarily thymidylate 
synthase, which is necessary for thymidine synthesis and tumor cell replication [3]. 
Cisplatin is an alkylating agent which crosslinks adjacent N7 centers on purine residues, 
damaging DNA, disrupting repair, and disrupting purine synthesis [4–6]. Disrupting DNA 
substrate supply results in S-phase arrest, DNA repair disruption, and eventually 
apoptosis [7,8]. Cisplatin also significantly disrupts calcium and reactive oxygen species 
(ROS) regulation, inducing cellular lesions which further sensitizes cancer cells to 
apoptosis [6].  
In contrast to the effect of PEM/CIS, i.e. DNA damage, bevacizumab is an anti-
VEGF (vascular endothelial growth factor) humanized monoclonal antibody. VEGF is an 
angiogenic potentiator which promotes the growth of endothelial tissue necessary for 
arteries, veins, and lymphatics. By limiting neovascular growth, and therefore blood 
delivery to neoplasms, bevacizumab exhibits limited antiproliferative properties [9]. 
More importantly, bevacizumab transiently induces a pruning effect on 
neovascular beds, which normalizes blood supply to neovascularly dense tissues (i.e. 
tumors) [10–12]. By normalizing blood supply, bevacizumab enhances 
chemotherapeutic (i.e. PEM/CIS) delivery to neoplasms [13,14]. 
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The effects of BEV-PEM/CIS are generalized i.e. any cell capable of uptaking the 
drugs are susceptible to their effects, especially rapidly-dividing cells such as myeloid 
cells [15].  Accordingly, BEV-PEM/CIS has a narrow therapeutic window and 
generalized side-effects [16]. Previous studies on BEV-PEM/CIS suggest that 
sequential administration of BEV-PEM/CIS (i.e. BEV before PEM/CIS) outperforms 
concomitant scheduling of BEV-PEM/CIS in treating NSCLC [11,17–19]. This makes 
BEV-PEM/CIS an attractive target for scheduling optimization via modeling and 
simulation, as a range of practical predictions – such as optimal scheduling in humans – 
can be made without the considerable time and resource investment required to 
conduct in vivo experiments. These predictions can be used to guide future studies, 
greatly accelerating drug development [20].  
In our previous work on BEV-PEM/CIS published in Imbs et al. 2017 [17], mice 
with NSCLC tumor xenografts were administered bevacizumab with PEM/CIS 
combination therapy (CT) in either concomitant, or delayed (i.e. bevacizumab before 
PEM/CIS) scheduling. The NSCLC tumors had been modified such that tumor growth 
could be tracked over time via either bioluminescence or fluorescence. Following 
previous theoretical investigations, the dataset generated from the mice with 
bioluminescent tumors was used to develop a semi-mechanistic PK/PD model for tumor 
dynamics in response to BEV-PEM/CIS [21,22]. The model was then used to predict the 
optimal scheduling gap between bevacizumab and PEM/CIS administration.  
The aim of this follow-up modeling work was to both refine and expand upon 
previous results on BEV-PEM/CIS CT using the much larger fluorescence dataset 
generated in Imbs et al. 2017 [17]. We first showed that the semi-mechanistic model 
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previously developed better explained the data than comparable models (i.e. we 
validated the previously developed structural model). Then, we refined the parameter 
estimates of the model, and used it to predict the optimal scheduling gap between 
bevacizumab and PEM/CIS administration. Next, we used stochastic simulations to 
explore the marginal loss in therapeutic efficacy when BEV-PEM/CIS was administered 
at a sub-optimal gap, the effect of bevacizumab dose scaling on population optimal gap, 
as well as the inter-individual variability (IIV) of optimal gap. Here, marginal loss in 
therapeutic efficacy refers to the loss in treatment efficacy from either scheduling the 
drugs with a gap shorter or longer than the optimal gap e.g. 1 day earlier or later than 
the optimal gap. Lastly, using literature human PK/PD models and parameter estimates, 




Comprehensive details on animals and the experimental procedure are available 
in Imbs et al. 2017 [17]. Briefly, on Day 0 of the experiment, tumors (ca 120,000 cells) 
consisting of H460 human NSCLC transfected with luciferase and the tdTomato gene 
(H460 Luc+ tdTomato+, Perkin Elmer France) were injected ectopically into the left flank 
of 90 mice. Animals were pathogen-free, immunocompromised, 6-week-old, female 
Swiss nude mice (Charles River, France). The mice were randomized into one of five 
treatment groups. The first study group (Control) received no treatment. The second 
treatment group (PEM/CIS) was administered both 100 mg/kg of pemetrexed IP and 3 
mg/kg of cisplatin IP on Days 14, 28, and 42 of the experiment. The third, fourth, and 
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fifth treatment groups (BEV-PEM/CIS) received the same PEM/CIS treatment as the 
second experimental group.  
In addition, the BEV-PEM/CIS treatment groups were administered 20 mg/kg IP 
of bevacizumab either concomitantly with the PEM/CIS administrations (group 3), 3 
days prior to each PEM/CIS administration (group 4), or 8 days prior to each PEM/CIS 
administration (group 5) – see table 4.S1 for administration tabulation.  
Tumor growth was monitored on a minimum bi-weekly basis using Ivis Spectrum 
imager (Perkin Elmer France) and images were acquired and analyzed using the Living 
Image 6.0. software (Perkin Elmer France). 
Mice were supplied with paracetamol supplemented water (e.g. 80 mg/kg/day) to 
prevent disease-related pain. Animals showing signs of distress, pain, cachexia (i.e. 
loss of 10% of body mass), or extensive tumor proliferation (i.e. within 2-3 cm) were 
euthanized. All animals were euthanized on Day 87 of the experiment. All experiments 
were approved by the local ethical committee at French Ministère de l’Education 
Nationale, de l’Enseignement Supérieur et de la Recherche, and registered as 
#2015110616255292. 
PK/PD Structural Model Building and Evaluation 
The PK models for bevacizumab, pemetrexed, and cisplatin were derived from 
previously published PK models in mice [23–25]. The parameters for these models were 
fixed to the typical values from those studies and assumed no IIV. 
The PD model was selected from a series of sequentially fit tumor growth and 
drug effect models. First – using only the control dataset – the exponential, linear-
exponential, and Gompertz growth model were cross-evaluated as models of 
unperturbed tumor growth [26]. Then, incorporating the full dataset into the fit, the log-
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kill effect of bevacizumab, log-kill effect of pemetrexed, and log-kill effect of cisplatin 
were each considered. The interaction effect between bevacizumab and PEM/CIS was 
included to represent the synergistic effect of bevacizumab. Following previous work for 
the effect of cytotoxic drugs, three cellular death compartments were included in the PD 
portion of the model to represent the delay between cellular damage due to PEM/CIS 
and cell death [27]. 
Competing models were evaluated numerically using Bayesian information 
criteria (BIC) and the precision of parameter estimates – defined as the relative 
standard error of the estimate (RSE). Observed vs. predicted plots, individual fit plots, 
and Visual Predictive Checks (VPCs) were produced to graphically assist model 
evaluation (as automated in Monolix 2018R2). VPCs were produced using the default 
estimation process for VPCs as of Monolix 2018R2 i.e. to create the 90% prediction 
intervals for the 10th, 50th, and 90th percentiles, 500 simulations are performed using 
random individual parameters and the design structure of the experiment. 
After model selection, the statistical correlations between random-effects were 
explored via visual inspection. Correlations plots between random effects were 
produced, defined as 𝜂𝑖,𝑡,𝜙1 vs 𝜂𝑖,𝑡,𝜙2  i.e. the random effect 𝜂, of individual 𝑖, at time 𝑡, of 
parameter 1, i.e. 𝜙1, vs the random effect 𝜂, of individual 𝑖, at time 𝑡, of parameter 2, i.e. 
𝜙2. The full posterior distribution of the parameters were used in place of EBEs to avoid 
visual artifacts due to shrinkage as suggested by Lavielle, et al, 2016 [28] and Pelligand 
L, et al, 2016 [29]. Statistical correlations between random effects were also numerically 
assessed using a Pearson correlation test at a P < .05 threshold. 
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SAEM convergence and final model parameterization were graphically assessed 
by inspection of search stability, distribution of the individual parameters, distribution of 
the random effects, individual prediction vs. observation, individual fits, distributions of 
the weighted residuals, as well as VPCs. 
The precision of parameter estimates was numerically assessed using RSE. The 
normality of random effects distributions, the normality of individual parameter 
distributions, and the normality of the distribution of residuals were each numerically 
assessed using a Shapiro-Wilk test (P < .05). The centering of the distribution of 
residuals (i.e. centered on 0) was numerically assessed using a Van Der Waerden test 
(P < .05). 
Parameter stability was assessed by comparing parameterizations resulting from 
random-initial starting value selection – as implemented in the Monolix assessment 
suite. The assessment suite performs 5 SAEM parameterizations in series using 
random initial parameter values uniformly drawn from the interval from approximately 
60% to 160% of final parameter estimates. The SAEM of the individual 
parameterizations was then tracked between runs - giving a range of parameter value 
estimates, RSEs, and log-likelihoods to compare. This assessment was used to ensure 
that the algorithm did not converge to a log-likelihood local minimum during the process 
of producing final parameter estimates. The settings described are the default as of 
Monolix 2018R2. 
Simulations 
Simulations were performed in R 3.4.4 using Simulx 3.3.0 [30] to simulate from 
Monolix run files. First, a function was built which accepted treatment schedule, 
parameter substitutions, dose, and number of individuals as input and produced a 
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simulated population as an output. This function was simply a convenience wrapper of 
Simulx for automation purposes and was verified by reproducing VPCs per treatment 
group. Simulation set 1 was used to predict the optimal gap between administration of 
bevacizumab and PEM/CIS. Simulation set 2 produced an estimate of the IIV of the 
optimal gap. Simulation set 3 examined the anticipated effect of varying the dose of 
bevacizumab on the optimal gap. Simulation set 4 scaled predictions of BEV-PEM/CIS 
efficacy to humans. All simulations were of population level response (i.e. simulated 
without RSE or IIV) except for simulation set 2 (simulated without RSE and with IIV) 
which used 1000 Monte Carlo samples. Further details are provided in the 
supplementary methods. 
Quality Assessment 




Measurement error was best described using a log-normal constant-error model 
(equation 1). The natural-log of each individual measurement, 𝑙𝑛(𝑦𝑖𝑗) with individual i 
and repetition j, was modeled as a measurement centered on the natural-log mean of 
𝑦𝑖𝑗  over j, i.e. 𝑙𝑛(𝑥̄ 𝑖), in addition to some residual error, 𝜖𝑖𝑗, normally distributed, 
centered on zero, and with standard deviation 𝑎. 
𝑦𝑖𝑗  =  𝑥̄ 𝑖 ⋅ 𝑒
𝜖𝑖𝑗    𝑤ℎ𝑒𝑟𝑒   𝑙𝑛(𝑦𝑖𝑗)  =  𝑙𝑛(𝑥̄ 𝑖) + 𝜖𝑖𝑗   |   𝜖 ∼ 𝑁(0, 𝑎)   (equation 1) 
The sGOF graphics and numerical analyses supported that a log-constant error model 
best fit the data. The log-constant error model was not rejected for both the 
Kolmogorov-Smirnov test for normality (P = .22) nor the Pearson chi-square normality 
test (P = .0509). In contrast, a constant error model was rejected by these two tests 
(see figure 4.S1 for further details). 
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PKPD Structural Model Building 
No outliers were identified during initial data exploration. Therefore, no collected 
data were excluded from model building.  
The pharmacokinetics of bevacizumab, pemetrexed, and cisplatin were each 
modeled using one-compartment models with first order IP absorption and first order 
elimination based on literature descriptions and PK parameter estimates (table 4.S3) 
[23–25]. Random effects (i.e. 𝜂𝑝𝑘) were set to 0 as individual PK was not reported in 
these experiments. 
A Gompertz function (equation 2) was found to best describe the unperturbed tumor 
growth 𝑉(𝑡), based on its fit performance over competing models, low RSE on 
parameter estimates, and literature-established descriptive quality. 
(α − β ∙ ln(𝑉 𝑉𝑐⁄ )) ∙ 𝑉        (equation 2) 
Due to relative sparseness in sampling, fitting more complex semi-mechanistic 
models of growth incorporating cellular quiescence, biphasic growth, and cell-type 
heterogeneity did not produce model fits with lower BIC or comparable precision in 
parameter estimates (RSE) to the simpler Gompertz model of tumor growth. 
Parameters 𝛼 and 𝛽 represent the proliferation rate of the tumor cells and rate of 
exponential decrease of the tumor relative growth rate, respectively. 𝑉𝐶 is the unit value 
of relative fluorescence units (RFU) corresponding to one cell, i.e. the proportionality 
constant between RFU and the number of cancer cells in the fluorescent volume. 
𝑉𝐶 was estimated externally from Monolix by conducting a naive-pooled, linear-
regression on the natural-log of the full dataset. The regression gave a rough estimate 
of 𝑉0 which was then scaled by the approximate number of cells injected at time 0 (ca. 
120,000 cells) to derive 𝑉𝐶 = 5.064 × 10
−4 RFU. 
After selecting an appropriate growth model, the log-kill effects of pemetrexed, 
cisplatin, and bevacizumab were each considered in parallel. The log-kill effect of 
bevacizumab was estimated as insignificant and removed from the model. The 
estimation of the log-kill effect of pemetrexed and cisplatin were found to be highly 
correlated. To reduce model complexity, only their combined concentration, 𝐶(𝑡), and a 







































𝜏𝑏𝑜𝑢𝑛𝑑  ∙  10
1 + 𝛿 ∙ 𝐴(𝑡 − 𝜏)
(α − β ∙ ln(𝑉 𝑉𝑐⁄ )) ∙ 𝑉 − γ𝑄𝐶𝑉
𝛾𝑄𝐶𝑉 − 𝑘 ∙ 𝑍1
𝑘 ∙ (𝑍1 − 𝑍2)
𝑘 ∙ (𝑍2 − 𝑍3)





































     (equation 3) 
 
𝐴(𝑡) represents the plasma concentration of bevacizumab. 𝑄(𝑡) represents the 
synergistic effect of improved vascular quality. In brief, the increase in neoplasm 
vascular quality due to bevacizumab typically occurs within a period of a few days after 
administration. To represent this delay in effect, time (𝑡) was delayed by 𝜏. Parameter 
𝛿 represents the proportional increase in PEM/CIS efficacy due to vascular quality 
improvement under bevacizumab therapy. 
The estimation of 𝜏 was bounded between 0 and 10 using the link function 
𝜏 = 𝜏𝑏𝑜𝑢𝑛𝑑 ⋅ 10, where 𝑙𝑜𝑔𝑖𝑡(𝜏𝑏𝑜𝑢𝑛𝑑) ∼ 𝑁(0,1). All other parameters were best estimated 
as log-normally distributed. The full statistical representation of individual parameters, 
𝜙𝑖, estimated via SAEM is shown in equation 4, where the full structural model is 
denoted by 𝐹. 
(equation 4) 
𝑦𝑖𝑗 =  𝐹(𝛷𝑖, 𝑡𝑖𝑗) ∙ 𝑒
𝑎 𝑖𝑗 , 𝑗  𝜖  {1, … , 𝑛𝑖} 
 












𝛼𝑖  =  𝛼𝑝𝑜𝑝 ∙  𝑒
𝜂𝛼,𝑖
𝛽𝑖  =  𝛽𝑝𝑜𝑝 ∙  𝑒
𝜂𝛽,𝑖
𝛾𝑖  =  𝛾𝑝𝑜𝑝  ∙  𝑒
𝜂𝛾,𝑖
𝛿𝑖 = 𝛿𝑝𝑜𝑝 ∙  𝑒
𝜂𝛿,𝑖
𝑙𝑜𝑔𝑖𝑡(𝜏𝑏𝑜𝑢𝑛𝑑𝑖)  =  𝑙𝑜𝑔𝑖𝑡(𝜏𝑏𝑜𝑢𝑛𝑑𝑝𝑜𝑝) + 𝜂𝜏𝑏𝑜𝑢𝑛𝑑 ,𝑖
𝑉0𝑖 = 𝑉0𝑝𝑜𝑝 ∙  𝑒
𝜂𝑉0,𝑖










,        𝑖 𝜖 {1, … ,𝑁} 
 
Cellular death due to chemotherapeutic treatment was modeled as a three-
compartment transition from the growth compartment to death [27]. The compartments 
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are labeled 𝑍1, 𝑍2, and 𝑍3 (numbering respective to their order) and transition between 
compartments is governed by intercompartmental clearance parameter 𝑘. 
After a period of manual exploration, 𝑘 was set to the value of 0.3. This choice is 
consistent with the parameterization made in Imbs et al [17]. This choice also limits the 
total transition time from the tumor mass compartment to cellular death to the order of a 
day which is consistent with upper limits of cellular death clearance [31]. 
The full tumor size, 𝑁, was the sum of the size of unperturbed cells, 𝑉, as well as 
the size of damaged cells undergoing cellular death i.e. 𝑍1 + 𝑍2 + 𝑍3. 
No correlations between random effects were statistically significant enough to 
be included in the final model (figure 4.S2). Full parameter estimates and model 
diagram are provided in table 4.1 and figure 4.1 respectively. Model diagnostics are 
collected in figure 4.2 through figure 4.4. 
Simulations 
Mouse simulations 
Simulating the experimental treatments with a range of administration gaps from 0 to 
10 days (step-size = 0.1 day) suggested that the optimal time delay between scheduling 
bevacizumab and PEM/CIS in mice is 2.0 days (simulation set 1).  
The simulated IIV of the optimal gap was relatively small. Only three values of 
individual optimal gap were produced. 96.5% of the virtual animals had an individual 
optimal gap of 2.0 days, 1.0% of the virtual animals had an individual optimal gap of 2.1 
days, and 2.5% of virtual animals had an individual gap of 1.9 days (simulation set 2). 
Scaling the dosage of bevacizumab to either 30 mg/kg or 10 mg/kg produced no 
effect in the estimated optimal gap and produced no effect in the IIV of the optimal gap 
(simulation set 3). 
Human simulations 
Simulations of the typical human response to chemotherapy and bevacizumab 
were performed using IV administration, two-compartment absorption, and first order 
elimination models and parameters [32–34]. Dosage, infusion time, and frequency of 
administration for BEV-PEM/CIS were adapted from the induction phase of the 
AVAPERL phase III clinical trial in BEV-PEM/CIS [2]. Average adult weight and BSA 
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were obtained from Center for Disease Control and literature estimates respectively 
[35,36]. 
Except for the proliferation rate of the tumor cells and rate of exponential 
decrease of the tumor relative growth rate (i.e. 𝛼 and 𝛽), the PD model and 
parameterization (𝛾, 𝛿, 𝜏, 𝑘) were reused exactly as they were determined in the mouse 
portion of the model. 𝛼 and 𝛽 estimates were obtained from Bilous et al. 2018 [37], 
where clinical NSCLC doubling times reported in Friberg and Mattson, 1998 [38] were 
used to estimate population 𝛼 and 𝛽 for NSCLC in humans. The value of VC came from 
the classical assumption that a 1 mm3 volume of tumor cells is approximately 106 cells 
[39]. V0 was arbitrarily set to 3 cm3. This scaling procedure resulted in an adapted 
model primarily constructed to predict optimal gap in humans. In contrast, the model 
relies on several implicit assumptions for scaling tumor response (see the 
supplementary methods). 
The full PK/PD model was then used to simulate the typical cancer growth under 
various administration schedules with a starting tumor volume of 3 cm3. Parameter 
estimates are reported in table 4.2, simulation administration schedule is reported in 
table 4.S2, and simulation summaries are depicted in figure 4.5. The estimated optimal 
gap between bevacizumab and PEM/CIS administration in humans was 1.2 days. 
Discussion 
By normalizing tumor vasculature, bevacizumab improves delivery of PEM/CIS to 
tumors and consequently PEM/CIS efficacy. Pemetrexed and cisplatin each have a 
narrow therapeutic window, and high toxicity. It is therefore critical that BEV-PEM/CIS 
doses are administered as efficiently as possible. This makes BEV-PEM/CIS a natural 
fit for modeling and simulation studies, as the drug scheduling can be optimized without 
the need for multiple time and resource intensive in vivo studies. In this analysis we 
conducted an in-silico study of the optimal administration of BEV-PEM/CIS in a 
xenograft, and human, model of NSCLC by constructing a mathematical model of tumor 
dynamics in response to BEV-PEM/CIS. In constructing that model, we were able to 
validate and refine previous modeling in BEV-PEM/CIS. Greater precision in parameter 
estimates was achieved through external estimation of 𝑉𝑐, external validation of the 
residual error model, as well as using the larger fluorescence dataset to obtain final 
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parameter estimates. Then, after exploring a range of predictions in mice, we scaled our 
model to predict optimal scheduling in humans. 
In the error modeling portion of the experiment, we demonstrated a strategy 
through which the choice of the error model can be validated externally to the primary 
dataset by including supplementary data collection in the experimental design. This 
simplified the error modeling step in the model building process. 
The next stage of this study consisted of determining whether the semi-
mechanistic model of tumor dynamics in response to BEV-PEM/CIS developed in Imbs 
et al. 2017 [17] best fit the unfit fluorescence data from the same study. During model 
building, we attempted to balance our model building procedure between model 
performance (empirical fit) and the underlying biology, an approach often referred to as 
the middle-out approach [40,41]. 
In selecting potential PD models of tumor growth, several semi-mechanistic 
models were fit to the experimental data. The Gompertz model and linear-exponential 
model performed comparably. The parameters of the Gompertz model were estimated 
with greater precision than the parameters of the linear-exponential model (RSE) where 
the linear-exponential model was fit with a lower BIC than the Gompertz model. 
Ultimately, the Gompertz model was chosen over the linear exponential model due to 
the physiological relevance of its construction. 
The parameterization of the final model was slightly unstable due to modest 
overparameterization. To compensate for this, 𝑘 was fixed to a reasonable physiological 
estimate to improve precision of parameter estimates, and the search for 𝜏 was 
bounded to reduce spurious individual parameter estimates. 
During structural model building, we confirmed the validity of the model 
previously published in Imbs et al. 2017 [17] We also reconfirmed the efficacy 
improvement of BEV-PEM/CIS dosing over PEM/CIS or control. We observed that a 3 
day gap in scheduling is superior to both concomitant scheduling and an 8 day gap in 
scheduling. We were also able to build on previous work by identifying with greater 
precision the parameters underlying the mathematical model of BEV-PEM/CIS in 
NSCLC-tumor bearing mice. 
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In our mouse simulations, the final tumor volume (after 67 days) in the optimal 
scheduling group with BEV-PEM/CIS (gap = 2.0 days) was 88.5% of the size of final 
tumor volume in the concomitant scheduling group. This is consistent with our 
experimental results i.e. that mice administered bevacizumab approximately 2.0 days 
before PEM/CIS have a moderately better response (i.e. greater tumor size reduction) 
to BEV-PEM/CIS than mice who are administered BEV-PEM/CIS concomitantly. We 
also found, through simulation, that scaling the dose of bevacizumab had no effect on 
the optimal gap and that IIV on gap is low. 
Predictions made by our model agree with previous findings in BEV-PEM/CIS 
scheduling. The order of the optimal scheduling delay (2.0 days) is within the 1 to 5 day 
gap predictions of previous studies [11,18,19]. Studies in tumor perfusion and 
bevacizumab showed Day 1 and Day 4 decrease in tumor perfusion which is consistent 
with the marginal predictions in our study i.e. optimal perfusion should be on the order 
of 2 days with comparable marginal losses on either side of that minimum [42]. 
After adapting our model to make simulations in humans, we predicted a robust 
response to both sequential and concomitant BEV-PEM/CIS scheduling. The final tumor 
volume (after 85 days) in the optimal scheduling group (gap = 1.2 days) was 52% of the 
size of the final tumor volume in the concomitant scheduling group. If these predictions 
are accurate, scheduling optimization could result in significant improvement in BEV-
PEM/CIS CT efficacy with no increase in toxicity.  
Since the dose of the therapeutics, their pharmacokinetics, administration 
method, and dosing schedules are different in humans vs. tumor-bearing mice, a shift in 
the optimal gap is expected between species. In this study, the discrepancy between 
the optimal gap in humans vs. NSCLC tumor-bearing mice is driven by the slow IP 
absorption of bevacizumab in mice (table 4.S3). 
When exploring marginal efficacy loss in sub-optimal administration schedules, 
we consistently found that the marginal cost of scheduling bevacizumab and PEM/CIS 
too close together in time was greater than the marginal cost of scheduling 
bevacizumab and PEM/CIS with too great of a gap in administration - in both mice and 
humans. This indicates that any potential clinical studies in antiangiogenics and 
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cytotoxics should weight scheduling recommendations toward scheduling at slightly too 
large of gap. 
Lastly, we would like to acknowledge some limitations of this study. The tumor 
microenvironment is known to be complex and varied. Tumor tissues contain necrotic 
pockets, heterogenous and dynamic microvasculature, and various sub-mutations 
which result in differential local growth rates and drug sensitivities. Furthermore, 
bevacizumab efficacy is potentially disease state dependent. Considering this biological 
heterogeneity and identifying biomarkers for measuring individual response would 
greatly improve future model predictions, model scalability between species, as well as 
modeling-based individualized therapy development. 
In summary, our analysis confirms previous findings in BEV-PEM/CIS scheduling 
while improving precision of parameter estimates, improving prediction quality and 
detail, and scaling the model to predict the optimal scheduling of BEV-PEM/CIS in 
humans. Antiangiogenics will continue to be useful agents in oncology. There are 
currently several other antiangiogenics regularly used in combination with cytotoxics 
which could potentially benefit from sequential administration (i.e. antiangiogenic then 
cytotoxic) [43]. Of note, bevacizumab is currently only approved for concomitant 
administration with chemotherapy in all of its indications e.g. lung cancer, breast cancer, 
gastric cancer, etc. This contrasts with the optimized sequential scheduling that model 
simulations suggest.  
There is a recent trend to develop model-informed drug development to optimize 
anticancer therapy. Our work highlights how mathematical modeling could help to refine 
clinical treatment modalities. The semi-mechanistic nature of this model allows it to be 
modularly reconfigured to extend predictions to other antiangiogenics as well as novel 
therapeutic paradigms such as the immune checkpoint inhibitor, monoclonal antibody 
pembrolizumab [44]. This work continues to lay the foundation for building systems 
pharmacology models of the effect of antiangiogenic and antiproliferative combination 
therapy in advanced NSCLC. Tortuous vasculature is a phenotype exhibited by many 
solid tumors, and predicting optimal antiangiogenic scheduling could greatly increase 
the efficacy of future oncology therapeutics and combination therapies [45]. 
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Supplementary Methods 
Simulation Details 
In simulation set 1, population response was simulated with no IIV and without 
RSE. The simulated treatment schedule consisted of 100 mg/kg of pemetrexed IP and 3 
mg/kg of cisplatin IP on Day 14, 28, and 42. 20 mg/kg IP of bevacizumab was virtually 
administered anywhere from 0 to 10 days (in steps of .1) before Day 14, 28, and 42. 
See table 4.S2 for details. 
The simulation was stopped after 67 virtual days. These simulations allowed the 
prediction of the optimal gap between administering bevacizumab and PEM-CIS. 
Efficacy of the drugs was assessed using AUC of the tumor growth over time as 
calculated by the spline method implemented in the R package DescTools 0.99.25 [1]. 
The optimal gap was defined as the administration scheduling gap which resulted in the 
lowest AUC of tumor growth vs. time over the simulated time period (t = 0 to t = 67). 
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In simulation set 2 the inter-individual variability of optimal gap was meticulously 
calculated using a virtual population of 1000 simulated mice. First, a set of parameters 
representing 1000 virtual mice was generated without RSE from the parameter 
distributions determined in the structural modeling phase. Then, the procedure from 
simulation set 1 was replicated per individual to estimate each individual optimal gap. 
Finally, the distribution of individual optimal gaps was assessed using the mode, 
standard deviation, and range as well as graphical methods such as a violin plot of 
count density. 
To produce simulation set 3, the procedure which generated simulation set 1 was 
repeated with scaled doses of bevacizumab. First, 10 mg/kg IP of bevacizumab was 
substituted for 20 mg/kg IP of bevacizumab. Second, 30 mg/kg IP of bevacizumab 
substituted for 20 mg/kg IP of bevacizumab. This was done to assess the effect of 
bevacizumab dosage on the estimated optimal gap. 
In simulation set 4 an analogous treatment regimen to simulation set 1 was 
simulated in a virtual NSCLC tumor-bearing human population using adapted human 
dosing recommendations (see table 4.S2). The random effects were set to zero and 
population response was simulated without RSE. Therefore, our simulations represent 
the average effect of varied administration schedule.  
The model used in simulation set 4 was a scaling of the model fit obtained from 
the xenograft mouse model. The PK portion of the model was built and parameterized 
using previously published PK models and typical parameter values. The PD parameter 
estimates were obtained from both the xenograft mouse model and from literature 
values. 
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Tumor dynamics in response to PEM-CIS-BEV were simulated using a 
scheduling gap of 0 days to 10 days in steps of 0.1. A graphical representation of the 
AUC vs. administration gap was generated to determine the optimal gap between 
bevacizumab and PEM-CIS dosing. 
Further Justification and Limitations of Scaling Procedure 
Xenografts were grown after subcutaneous implantation in the mice flank, and 
not directly in the lungs. This is because monitoring tumor growth of lung orthotopic 
xenografts with non-invasive techniques is limitingly difficult due to both the rapid 
movements of the chest in mice during imaging, and photon emission attenuation by the 
high amount of water in lung tissues. Consequently, ectopic xenografts were considered 
as the more robust experimental model for data collection. The molecular profile of 
xenografts has a high degree of similarity with the molecular profile of the primary 
tumors from which the xenograft was derived [2]. This indicates that there is a 
compositional heterogeneity between xenografts and primary tumors. In addition, 
human NSCLC H460 cells are an experimentally established paradigm for modeling 
NSCLC tumors [3–5]. 
As mentioned in the manuscript, dosage, administration route (IV), frequency of 
administration, and infusion time were adapted from the induction phase of the 
AVAPERL phase III clinical trial in BEV-PEM/CIS [6] and are summarized in a table 
4.S2. 
The human PK portion of the model was re-parameterized using IV 
administration, two compartment absorption, and first order elimination models and 
parameters from Lu et al. 2008 [7] (bevacizumab), Latz et al. 2006 [8] (pemetrexed), 
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and Urien et al. 2005 [9] (cisplatin). These PK studies were all performed in diverse 
populations of cancer patients i.e. not all patients were NSCLC patients. 
Human 𝜶 and 𝜷 estimates came from Bilous et al. 2018 [10], where human 𝛼 and 
𝜷 parameter values were estimated from clinical NSCLC data. In contrast, 𝜸, 𝜹, and 𝒌 
were reused exactly as they were determined in the mouse portion of the model, as 
human parameter values and efficacy data for BEV-PEM/CIS are not available in the 
current literature. Theoretically, these parameters should not affect the predicted 
optimal gap, but they could affect the scale of efficacy in our simulations. 
𝝉 was reused as determined in the mouse portion of the model for both 
physiological and literature value availability reasons. With respect to mechanism of 
action, bevacizumab acts by inhibiting VEGF-A produced by NSCLC cells [11]. Previous 
work has established that bevacizumab’s effect is asymptotic [12,13]. In other words, if 
bevacizumab is maintained at some minimum inhibitory plasma concentration, its 
effects on VEGF-A signaling should remain consistent between xenograft and primary 
tumors. This was the physiological basis for reusing 𝝉 when scaling the model to make 
predictions in humans as VEGF-A signaling should remain relatively constant between 
primary and xenograft tumors [2]. 
Using this adapted parameterization, we estimated both optimal schedule of 
administration of BEV-PEM/CIS in humans and the marginal effects of a sub-optimal 
administration schedule of BEV-PEM/CIS in humans (i.e. bevacizumab administered 
too many or too few days before PEM/CIS). Full parameter estimates are available in 
Table 2. 
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Several limiting assumptions were made in our simulations of BEV-PEM/CIS 
pharmacodynamics in humans. First and foremost, we have assumed that the immune 
system of the immunocompromised mice is comparable to that of a cancer patient, 
which is highly unlikely. Second, we have implicitly assumed that the combination effect 
of BEV-PEM/CIS on tumor growth is similar in humans vs. mice. This assumption 
further holds for the prediction of BEV-PEM/CIS adverse effects and sensitivity to 
chemotherapeutics, such as thymidylate synthase inhibition with PEM. Lastly, we chose 
to model tumor response with respect to total concentrations of bevacizumab, 
pemetrexed, and cisplatin. Although unbound concentrations are undoubtedly more 
relevant than total drug levels, detailed PK parameter values for bevacizumab, 
pemetrexed, and cisplatin unbound concentrations are not available in the current 
literature. However, differences in protein binding typically do not affect the time-course 
of drug effect, and hence should have negligible impact on the estimated optimal gap 
between bevacizumab, pemetrexed, and cisplatin.  
In summary, the predictions of efficacy in humans produced in this study are not 
meant to be substituted for clinical testing. Indeed, this model was primarily adapted to 
scale the optimal scheduling gap from the xenograft model to humans. Both the 
predicted optimal gap and predicted efficacy require further validation with clinical data. 
However, our scaled model of BEV-PEM/CIS in human NSCLC and prediction of 
optimal gap should help guide clinical testing conditions for optimal sequential 





Tables and Figures 
Table 4.1 PD Model Parameters for Tumor Proliferation in NSCLC-Xenografted Mice 
Model parameter estimates (fixed and random-effects) as well as standard errors as 
determined by the Stochastic Approximation Expectation-Maximization algorithm as 
implemented in Monolix 2018R2. α and β represent the proliferation rate of the tumor 
cells and rate of exponential decrease of the tumor relative growth rate, respectively. γ 
was used to model the log-kill effect of pemetrexed and cisplatin’s combined 
concentration. δ represents the proportional increase in pemetrexed/cisplatin efficacy 
due to vascular quality improvement under bevacizumab therapy. τ was the time delay 
in bevacizumab effect. 𝑉0 represents the volume of cells at time 0. 𝑘 governs 












Model Parameter Estimate SE RSE (%) IIV IIV (CV%) 
𝜶 0.77 day
-1
 0.0081 1.06 0.037 4.76 
𝜷 0.04 day
-1
 0.0005 1.16 0.015 33.55 
𝜸 35.74  (mg·day)
-1
 6.36 17.79 0.46 1.28 
𝜹 3.73  (mg·day)
-1
 0.92 24.70 0.35 9.51 
𝝉  1.19 days 0.017 1.50 0.17 14.50 
𝑽0 3.4 RFU* 0.27 22.55 1.73 143.03 
𝒌 0.30 day
-1
 - - - - 
Residual Error Variance 0.43 0.01 2.55 - - 




Table 4.2 Parameterization for Simulations of NSCLC treated with BEV-PEM/CIS in 
Humans 
Except for the proliferation rate of the tumor cells and rate of exponential decrease of 
the tumor relative growth rate (i.e. α and β), the PD model and parameterization were 
reused exactly as they were determined in the mouse portion of the model. α and β 
estimates were obtained from Bilous et al. 2018 [37], where clinical NSCLC doubling 
times reported in Friberg and Mattson, 1998 [38] were used to estimate population α 
and βfor NSCLC in humans. The value of VC came from the classical assumption that a 
1 mm3 volume of tumor cells is approximately 106 cells [39]. V0 was arbitrarily set to 3.0 
cm3. 𝑉1,  𝑉2, 𝑄, and 𝐶𝑙 represent volume of compartment 1 and peripheral compartment 




Table 4.S1 Administration (adm) Schedule for the Five Experimental Groups 
The cytotoxics consisted of an administration of both 100 mg/kg of pemetrexed IP and 3 




Pharmacokinetics  Pharmacodynamics 
Drug Pemetrexed Cisplatin Bevacizumab  𝜶  0.0284 day
-1
 
𝑽1 (L) 12.9 22.3 2.8  𝜷  1.03E-3 day
-1
 
𝑽2 (L) 3.38 77.0 2.9  𝜸  35.7 (mg·day)
-1
 
𝑸 (L/day) 20.7 456.0 0.6  𝜹  3.73 (mg·day)
-1
 
𝑪𝑳 (L/day) 131.9 6.5 0.2  𝝉  1.19 days 
Infusion Time (min) 10.0 120.0 60.0  𝑽𝟎  3 cm
3
 
     𝒌  0.3 days 






Table 4.S2 Administration (adm) schedule for the simulated human individual 
Drugs were administered on three separate occasions, the 17th, 38th, and 59th 
experimental day, via IV administration. Bevacizumab administration (adm) was varied 
between simulation run i.e. it was administered anywhere between 0 and 10 days 
before Pemetrexed-Cisplatin. The simulation was stopped on virtual experimental day 
85. 
 
Table 4.S3 Pharmacokinetic parameters for pemetrexed, cisplatin, and bevacizumab in 
mice 





Figure 4.1 Structural Model Diagram 
The scheme of the structural model is depicted to the right. Unperturbed cells grow at 
rate governed by 𝛼 and 𝛽. When a cytotoxic is introduced into the system, the cytotoxic 
impairs the growth of the tumor by sending cells into a death succession. The 
parameter which determines the cytotoxic efficacy, 𝛾, is scaled by both the 
concentration of cytotoxics, 𝐶(𝑡), and the volume of the tumor, 𝑉(𝑡).  Bevacizumab 
improves vascular quality, 𝑄(𝑡), after time delay, 𝜏, which scales the cytotoxic effect by 
parameter 𝛿. When a cell is damaged by cytotoxics it begins a progression from 
unperturbed growth – compartment 𝑉(𝑡) – to damage compartments 𝑍1 through 𝑍1. 
Eventually the cell exits the tumor volume as it dies. The rate of transfer between 
damage compartments is governed by intercompartmental clearance parameter 𝑘. 
 
Figure 4.2 Standard Goodness-of-Fit Diagnostic Plots. 
On the left is individual predictions vs. observations and on the right are the 
individualized weighted residuals (IWRES) vs time. During model fitting, observations 
were natural-log-transformed to stabilize predictions. Therefore, residuals, predictions, 
and observations are natural-log-transformed in these figures. The predictions are 
approximately normally distributed. On the left, the one-to-one prediction line is the 
center solid black line, the spline (average agreement between individual prediction and 
observation) is solid orange, the dashed black lines are the borders of the 90% 
prediction interval. On the right, the zero residual error line is the center dashed black 





Figure 4.3 Sample of Individual Fits 
The blue dots represent individual observations while the solid violet line represents 
individual fits. Some mice – e.g. mice in the control group – were not tracked for the full 
course of the study. These animals experienced complications due to the experiment 
and either spontaneously passed or were euthanized to prevent excessive suffering. 
 
 
Figure 4.4 Combined and Stratified Visual Predictive Checks  
The blue lines are the 10th, 50th, and 90th empirical percentiles calculated for each 
unique value of time. Blue and pink areas represent 90% prediction intervals for the 10th 
(blue), 50th (pink), and 90th (blue) percentiles. Prediction intervals are calculated by 
Monte Carlo simulation. To create prediction intervals for each unique value of time, 500 
simulations are performed using random individual parameters. The red areas and red-
circled points represent areas where empirical measurements fall outside of the bounds 




Figure 4.5 Human Pharmacodynamic and Pharmacodynamic Simulations Summary  
To produce these figures, bevacizumab (BEV) was administered anywhere from 0 to 10 
days (in steps of 0.1) before pemetrexed/cisplatin (PEM/CIS) was administered. Tumor 
growth was simulated from 0 to 67 days with no IIV and no RSE. In the top figure, AUC 
of tumor growth vs gap (0 to 10 days) is depicted. In the middle figure, tumor dynamics 
over time, with gap indicated by color, are depicted. In the bottom panel, the PK of BEV-
PEM/CIS is depicted with gap indicated by color. The top figure indicates that the 
optimal scheduling gap is 1.2 days and the middle figure depicts the difference in tumor 
volume between administration gaps. The patient with optimal scheduling had a final 
tumor volume approx. 30% the size of the concomitant scheduling. 
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Figure 4.S1 Comparison of Error Models 
In the left column are the probability density distributions (red) vs. theoretical normal 
distributions (blue) for each error group. On the right are the quantile-quantile plots 
which compare the quantiles between the theoretical and observed distributions of 
points. Below each set of sGOF graphics are the scores for the Kolomogorov-Smirnov 
normality test as well as the Pearson chi-square normality test. Graphically, the log-
constant error model outperformed the constant error model. Numerically, the log-
constant error model outperformed the constant error model in both the Kolmogorov-




Figure 4.S2 Correlation Between Parameter Estimates 
The Pearson’s Correlation Coefficient is displayed in each correlation and the red line is 
the linear regression of the conditional distribution. 
 
Figure 4.S3 SAEM Convergence Diagnosis 
Above are various SAEM convergence results produced by Monolix’s assessment suite. 
The best performing (defined as lowest -2 loglikelihood) parameterization (in yellow) 
closely matches our final parameter estimates. The assessment indicates that there is 
some degree of instability in parameter estimates. But, variance in parameter estimates 
is relatively low and RSE on final parameter estimates is low, indicating that we’ve 
achieved a reasonable balance between the empirical fit and underlying biology. 




Figure 4.S4 Simulated Tumor Growth and Response – Mouse Model 
Above is the 3D surface of simulated tumor growth response (dimension 1) with respect 
to gap (dimension 2) and time (dimension 3) in mice. This 3D surface allowed us to 
more intuitively understand the effect of varied administration schedules. It is available 
for manipulation at https://plot.ly/~Benjamin-PKPD/15/#/. 
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Figure 4.S5 Simulated Tumor Growth and Response – Humans 
Above is the 3D surface of simulated tumor growth response (dimension 1) with respect 
to gap (dimension 2) and time (dimension 3) in humans. This 3D surface allowed us to 
more intuitively understand the effect of varied administration schedules. It is available 
for manipulation at https://plot.ly/~Benjamin-PKPD/17/#/.   
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Abstract 
First-line antiproliferatives for non-small cell lung cancer (NSCLC) have a 
relatively high failure rate due to high intrinsic resistance rates and acquired resistance 
rates to therapy. 57% patients are diagnosed in late-stage disease due to the tendency 
of early-stage NSCLC to be asymptomatic. For patients first diagnosed with metastatic 
disease the 5-year survival rate is approximately 5%. To help accelerate the 
development of novel therapeutics and computer-based tools for optimizing individual 
therapy, we have collated data from 11 different clinical trials in NSCLC and developed 
a semi-mechanistic, clinical model of NSCLC growth and pharmacodynamics relative to 
the various therapeutics represented in the study. In this study, we have produced 
extremely precise estimates of clinical parameters fundamental to cancer modeling 
such as the rate of acquired resistance to various pharmaceuticals, the relationship 
between drug concentration and rate of cancer cell death, as well as the fine temporal 
dynamics of anti-VEGF therapy. In the simulation sets documented in this study, we 
have used the model to make meaningful descriptions of efficacy gain in making 
bevacizumab-antiproliferative combination therapy sequential, over a series of days, 
rather than concurrent. 
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Reference Nomenclature and Abbreviations for Equations 
afolate The antifolate action of a cytotoxic drug i.e. pemetrexed 
apo  Apomab aka DAB4, its chimeric derivative chDAB4, or PRO95780 
auc The area under the curve of drug concentration over time, usually 
interpreted as a measure of exposure 
bev  Bevacizumab 
car  Carboplatin 
cc  Concentration, usually concentration as a function of time 
cis  Cisplatin 
doc  Docetaxel 
dr5 The mechanism of action of Apomab, a monoclonal antibody 
against death receptor 5 
eff  Effect 
egfr The egfr-based (endothelial growth factor receptor) mechanism of 
erlotinib 
erl  Erlotinib 
gem  Gemcitabine 
kk  Rate of passage between compartments 
microt  The microtubule-inhibition mechanisms of paclitaxel and docetaxel 
n  Sum of primary all tumor volumes i.e. v + vi + z1 + z2 + z3 
dnasub The mechanism of action of gemcitabine whereby it masquerades 
as a functional nucleoside only to cause masked chain termination 
when incorporated into DNA 
pac  Paclitaxel 
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pem  Pemetrexed 
plat The class of cytotoxics whose mechanism involves platinum i.e. 
cisplatin, carboplatin, etc. 
Qα, Qρ The effects whereby certain drugs limit the rate of growth of the 
tumor e.g. cell cycle arrest, nutrient supply disruption, etc. 
Qγ  The effect whereby certain drugs kill tumor cells directly 
t  Time in days 
v  Primary tumor volume in cm3 
vi Volume of tumor cells which are injured by vegf and microt drugs 
vegf The anti-vegf (vascular endothelial growth factor) mechanism of 
bevacizumab 
z1–3  Irreversible cell death compartments 
wd A scaling factor between drug concentration and cytotoxic effect 
λd  Scaling factor between drug exposure and resistance 
Introduction 
With an estimated 135,000 deaths per year in the United States, lung cancer has 
the highest mortality rate of any cancer type (1). Approximately 85% of those deaths are 
attributable to non-small cell lung cancer (NSCLC). Often, NSCLC is not detected until 
late-stage disease as the early progression produces relatively few symptoms. First-line 
therapeutics for the management of metastatic or recurrent NSCLC (i.e. late-stage 
NSCLC) include combination chemotherapies (including platinum-based doublets) 
alone, or associated with immune checkpoint inhibitors (i.e. PD-1/PD-L1 or CTLA4 
inhibitors) or antiangiogenics (e.g. bevacizumab, BEV). However, first- and second-line 
therapies have a relatively high failure rate. As an example, in the recent ARIES 
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observational cohort study of first-line treatment involving bevacizumab the failure rate 
was approximately 51%. 
Acquired or intrinsic drug resistance is a major cause for therapeutic failure in 
NSCLC. In a previous study of resected NSCLC by d’Amato et al., intermediate to 
extreme resistance to carboplatin was found in 68% of NSCLC cultures (vs. 63% and 
40% for cisplatin and paclitaxel, respectively). Likewise, in the KEYNOTE-001 study 
completed last fall, NSCLC patients receiving pembrolizumab had an objective 
response rate of 19.4%, indicating that a vast majority of individuals did not significantly 
respond to therapy. Patients are also sometimes forced to cycle off chemotherapy due 
to excessive side-effects. Chemotherapeutics are notorious for broad and severe off-
target effects that exacerbate underlying vulnerabilities – e.g. chronic kidney disease. 
After initial therapeutic options fail, many patients choose to enroll in clinical trials to 
receive experimental therapies (2). Though the prognosis for NSCLC patients is 
improving, at this time the 5-year survival rate in non-small cell lung cancer (NSCLC) is 
only approximately 20%. For the 57% of lung cancer patients first diagnosed with 
metastatic disease the 5-year survival rate is approximately 5% (3). Therefore, there is 
a critical need to improve the efficacy of existing therapeutics, to develop a better 
understanding of individualized NSCLC therapy, and to accelerate experimental 
therapeutic development. Mathematical modeling is a key strategy for addressing these 
needs, as its use in cancer is a proven method for solving problems in optimization and 
precision medicine (4–7). 
Mathematical modeling of drug pharmacokinetics and pharmacodynamics is an 
extremely efficient method for optimization of therapeutic dosing schedules, without the 
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considerable time and resource investment required to conduct a suite of in vivo clinical 
trials. Using this computational platform, one can leverage data from multiple studies, 
involving diverse patient populations, varying drug combinations and administration 
schedules, to build a series of “what if” scenarios and derive the best scheduling and 
dosing of therapeutic drug intervention in a given set of patients. 
Bevacizumab is an important targeted therapy in treating NSCLC that has 
performed strongly when used in combination with a broad spectrum of 
antiproliferatives. Bevacizumab is an anti-angiogenic, and therefore inhibits the 
development of the neovascular architecture supporting tumor proliferation. 
Neovascular growth disruption is directly cytotoxic. Bevacizumab has also been shown 
to induce a transient period of perfusion normalization. This perfusion normalization 
improves the delivery of cytotoxics to the tumor resulting in improved efficacy of the 
cytotoxic. Because efficacy is improved, prescribing cytotoxics in combination with 
bevacizumab often allows clinicians to reduce the dosage of primary cytotoxics, thereby 
reducing the side-effect burden on the patient (8). 
Previously, we have shown experimentally and described mathematically the 
time-course of this transient perfusion-normalization in a xenograft-murine model of 
NSCLC (9). In that experiment, pemetrexed-cisplatin (PEM/CIS) was administered 
sequentially with bevacizumab (BEV). By varying the gap between bevacizumab and 
cytotoxic administration, we were able to estimate the time-course of vascular 
normalization, as well as several other parameters used to build a pharmacokinetic-
pharmacodynamic (PKPD) description of NSCLC growth and response to BEV-
PEM/CIS. 
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In our previous model description, we could predict that administering BEV and 
PEM/CIS sequentially with a gap of 1 day, rather than concurrently, would improve the 
efficacy of this combination (quantified as final tumor volume) by more than 50% without 
the need for increasing therapeutic doses. However, optimal scheduling of this 
combination in humans has yet to be verified with large sets of clinical data, and the 
model needs to be generalized to other combination therapies, including immune 
checkpoint inhibitors. 
Our previous preclinical study is a demonstration of a proven paradigm of 
therapeutic development that could become especially impactful in NSCLC. In this 
paradigm, scientists develop novel and individualized therapeutic strategies from 
existing and approved therapeutics (2,10). Additionally, there is a wealth of data 
currently available from clinical data-sharing services such as Vivli, CSDR, Project 
Datasphere, YODA and others. When using previously produced data, researchers 
obviate the need for human or animal participants. The cost and time required to clean 
and organize the data, build the model, evaluate the model, and simulate clinical trials is 
drastically less than that required when designing and performing new clinical trials. 
Clinical trials are usually only designed to test a sparse number of medications and 
scheduling strategies over the course of the study. Via simulation, we can trial a vast 
number of medication combinations and scheduling strategies simultaneously. 
Data from clinical trials will not always be directly comparable due to, for 
example, variations in experimental design, differences in operating procedure, and 
differences in patient cohort characteristics. This variation can be an advantage of 
pooling datasets from separate trials if the statistical framework for analysis is able to 
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account for and elucidate any potential sources of variation. Non-linear mixed effects 
(NLME) modeling of tumor proliferation and response is a proven framework for pooling 
data to model-build (9,11,12) 
In this study, we have implemented these principles to build a unified, semi-
mechanistic model and platform for scheduling bevacizumab in combination with 
several approved therapeutics in NSCLC. Specifically, we have collated individual tumor 
progression data from 11 different clinical trials (> 8000 stage II through stage IV, 
metastatic, and non-metastatic patients) involving BEV and multiple chemotherapies 
such as PEM, CIS, apomab, paclitaxel, carboplatin, gemcitabine, and erlotinib. These 
data were made available to us through a data sharing agreement with vivli.org. Our 
overall objectives in this study are to (1) generalize our model of NSCLC growth and 
response to BEV-PEM/CIS to the greater set of combination therapies and modes of 
action represented in our large clinical database, and (2) characterize the time-course of 
resistance for those registered therapeutics in humans. 
Methods 
Literature Search and Review 
To build our model, we sought access to data using very broad criteria. Briefly, 
we were interested in requesting access to data from clinical trials where bevacizumab 
had been used in combination with other therapeutics to treat NSCLC. To build on 
previous modeling efforts, it was necessary for most studies to include records of 
individual patient tumor sizes over time. After reviewing several potential data access 
providers with which we could partner, we applied for data access through the Clinical 
Study Data Request (CSDR) portal. We were able to identify 11 different studies 
available through CSDR’s platform which met our requirements (Table 1) and were 
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permitted access to a secure server containing the datasets beginning on January 6th, 
2020. 
Due to contractual obligations between the data owners (Roche, Eli Lilly) and 
data access provider (CSDR), our project and access to the datasets were moved to a 
secure server managed by Vivli on September 22nd, 2020. During this transfer process, 
we requested access to, and were granted access to, 5 additional datasets involving 
immune-checkpoint inhibitors and NSCLC which were not available at the time we first 
applied for access through CSDR. 
Data Processing and Collation 
Data annotation, units, organization, and shorthand is highly variable between 
datasets. This variability makes collating and preparing large datasets for mathematical 
modeling a challenging, and highly error-prone task. 
To reduce the possibility of introducing mistakes into the datasets during 
collation, we systematized the iterative collation of datasets. First, we identified the 
comma separated value files containing the most relevant base information. The 
information we were interested in for initial model-building was individual, tumor 
identifier, tumor type, tumor size, and drug administration details all organized 
longitudinally. Data were then imported into R (version 3.5.2) to be normalized for 
import into our NLME parameter estimation software (Monolix Suite version 2020R1, 
Lixoft). Normalization consisted of formatting the data as recommend by Lixoft (15), as 
well as matching units to an internal dictionary of standards – tumor measurements in 
cm, amount administered in mg, etc. 
After each dataset was produced, the data was explored visually with a 
combination of R as well as Datxplore (Monolix Suite version 2020R1) to check for 
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inconsistencies. Finally, the individual datasets produced in analyzing each individual 
study were bound into one single comma separated value file. As a final quality check, 
the final dataset was re-imported in R, and subset down to individual studies. Then, the 
processed studies were compared with the raw files from the clinical trials for 
consistency. Data were both received and maintained in a fully anonymized format to 
protect patient privacy. 
Non-Linear Mixed Effects Modeling and Characterizing Individual Variation 
The recorded data (yij) were pooled and used to estimate model parameters via 
the stochastic approximation expectation maximization algorithm (SAEM) as 
implemented in Monolix. After estimating population parameters (μ) and variance, 
individual parameters (ϕi) were estimated using the modes of the individual estimated 
posterior distributions. The posterior distributions were estimated using a Markov-Chain 
Monte-Carlo (MCMC) procedure. NLME models were written as previously described 
(Pelligand et al., 2016; Sheiner & Ludden, 1992) (Equation 1). 
Equation 1: 
𝑦𝑖𝑗 = 𝐹(𝝓𝑖,   𝜷𝑖,    𝑡𝑖𝑗) + 𝐺(𝝓𝑖 ,   𝑡𝑖𝑗) ∙ 𝑖𝑗      |      𝜺𝑖𝑗~𝒩(𝟎,   𝜎
2) 
𝝓𝑖 = ℎ(𝝁,   𝜼𝑖,   𝜷𝑖)      |      𝜼𝑖𝑗~𝒩(𝟎,   𝛀,    𝜔
2) 
𝑗 ∈ 1,… , 𝑛𝑖 , 𝑖 ∈ 1,… ,𝑁 
Model predictions (F(ϕi,  βi,  tij)) for the ith individual at the jth timepoint were 
written as a function of individual parameters, individual covariates (βi), and time (tij). 
The residuals were modeled as G(ϕi, tij) ∙ εij. 
Individual parameters are modeled with function h(μ,  ηi, βi). Interindividual 
variability, ηi, are distributed normally with mean 0, variance-covariance matrix Ω, and 
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variance ω2. Typically, h(μ,  ηi, βi) is a lognormal link function (Equation 2). In cases 
where ϕi is bounded, h(μ,  ηi, βi) was typically a lognormal link function (Equation 3). 
Equation 2: 






) = 𝑙𝑜𝑔 (
𝜇
1 −  𝜇
) + 𝜂𝑖 + 𝛽𝑖 
Model Building 
PKPD models were built in multiple development phases. First, we reproduced 
previously established models of therapeutic PK within our modeling project using 
Mlxtran. Then, we created several sample sets with between 5% and 10% of the 
complete dataset for initial model building. This shortened calculation time and reduced 
computational complexity. Next, we identified our preferred base candidate models for 
PD and implemented them in Mlxtran. Finally, using manual exploration and cursory 
SAEM parameterizations, we were able to determine reasonable parameter estimates 
with which to initialize our parameter search. 
The PK portion of our PKPD model was implemented using previously published 
human PK models and parameter values. PK models were written in Mlxtran. We 
verified PK model integrity by simulating trivial scenarios with known outcomes using 
Mlxplore. If outcomes simulated deviated from expectations, the code was reviewed for 
inconsistencies. 
To begin building our model of NSCLC PKPD, we used exploration to 
parameterize two base models of NSCLC PD. The first model parameterized was the 
traditionally used Claret model of tumor growth and response to anti-proliferatives. The 
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second base model implemented was built on our previous Gompertzian model of BEV-
PEM/CIS published elsewhere. 
To initially parameterize these candidate models, we visually explored potential 
initial parameter spaces using smaller sample subsets. Once we had a set of potential 
initial parameter values, we ran the SAEM algorithm on these sample sets to determine 
numerical stability of these parameter values. This process would result in loops of 
exploration and parameterization leading to further exploration and parameterization. 
Once we had implemented a PKPD model in Mlxtran and had reasonable initial 
parameter estimates, we were able to fit the model to the full dataset using the SAEM 
method. After fitting base models of PKPD, we were able to evaluate and iteratively 
improve on the deficiencies in fit using numerical experimentation, model exploration, 
goodness-of-fit metrics, traditional analysis, as well as reviewing previously published 
theories of NSCLC response to various therapeutics. For example, using simulation 
engines like Simulx and Mlxplore, we were able to test whether known biological 
phenomena were reliably reproduced by the model. Using model evaluation tools 
(below), we were able to test whether our fit appropriately met the assumptions made 
for NLME modeling. If the model did not produce individual fits which closely matched 
measurements, we used fundamental compartmental modeling concepts to add 
parameters, and therefore flexibility, to the model. 
Our primary structural concerns were modeling individual tumor growth and 
response, modeling both acquired and intrinsic resistance, modeling individual drug 
effects and interactions, as well as modeling the timescale of perfusion enhancement 
via bevacizumab. Modeling perfusion enhancement via bevacizumab was especially 
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important as it was the primary structure that would allow us to determine the optimal 
predicted scheduling of sequential bevacizumab and various anti-proliferatives. 
Model Evaluation 
We employed state-of-the-art model building techniques to develop our model 
into a meaningfully complete description of the variation in the dataset and evaluate the 
quality of model. This broadly required us to evaluate quality of fit, validate assumptions 
made about variance, test correlation between individual parameters with both other 
individual parameters as well as covariates, consider various statistical formulations of 
individual parameters, determine precision of individual parameter estimates, and finally 
measure models against one another. 
Quality of fit was determined using both goodness-of-fit plots and summary 
statistics. Stability of parameter estimates was assessed by both inspection of SAEM 
search, attainment of auto-stop criteria as implemented in Monolix, and whether 
randomized (but still local) initial starting parameters converge to the same set of 
parameter estimates. Accuracy of individual fits was assessed using a sample of 
individual plots, an observations-vs-predictions plot using the full conditional distribution, 
a scatter plot of the residuals, as well as the corrected Bayesian information criteria 
(BIC) – estimated via importance sampling). 
Assumptions of variance were validated by plotting the conditional distribution 
against theoretical distributions as well as standard statistical tests. Within the NLME 
framework, random effects and residuals are assumed to be predictably distributed – 
usually normally or functionally-linked to normal. We used the Shapiro-Wilk test of 
normality to determine normality, and Van Der Waerden test to determine symmetry of 
distributions about 0. 
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Correlation between individual parameters and other individual parameters or 
covariates were tested with a Pearson’s correlation test and ANOVA, respectively. 
Plotting these relationships assisted in determining the nature of these correlations. 
Precision and accuracy of the final model was assessed to evaluate models 
against one another. Precision of parameter estimates was made using relative 
standard error (RSE). Overall model quality of fit was evaluated BICc. Diagnostic plots 
assisted in comparing models with similar overall performance. 
Clinical Trial Simulations 
In our clinical trial simulations, we hoped to determine what benefit (if any) 
sequentially administering therapy with bevacizumab produced. To do this, we took the 
individual fits from the experimental arms of the trials and simulated them with various 
gaps between bevacizumab and treatment using Simulx (Monolix Suite version 2020R1, 
Lixoft). The highest performing gap was then compared with the experimental standard. 
Study Details 
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and 
Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus 
Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab 
in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer 
Between 2008 and 2014, 939 patients were administered either bevacizumab + 
pemetrexed + carboplatin (experimental arm) or bevacizumab + paclitaxel + carboplatin 
(comparator arm) to treat phase 3 NSCLC. Primary outcome was overall survival time 
from baseline to date of death (any cause). ClinicalTrials.gov Identifier: NCT00762034 
A Study of Pemetrexed and Bevacizumab for Participants With Advanced Non-
Small Cell Cancer 
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Between 2009 and 2013, 109 patients were administered bevacizumab + 
pemetrexed + carboplatin (single treatment arm) to treat stage IIIB or stage IV NSCLC 
that was not amenable to curative therapy. Primary outcome was progression free 
survival from baseline. Progression was scored using response evaluation criteria in 
solid tumors (RECIST criteria). ClinicalTrials.gov Identifier: NCT01004250 
A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage 
Non-Small Cell Lung Cancer (APM4074g) 
Between 2007 and 2010, 128 patients were administered either bevacizumab + 
carboplatin + paclitaxel + PRO95780 (experimental arm), or bevacizumab-
pemetrexed/carboplatin (single treatment arm) to treat stage IIIB or stage IV NSCLC 
that was not amenable to curative therapy. Primary outcome was progression free 
survival from baseline. Progression was scored using response evaluation criteria in 
solid tumors (RECIST criteria). ClinicalTrials.gov Identifier: NCT00480831 
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small 
Cell Lung Cancer (NSCLC) 
Over a period of 6 years starting in 2005, 1044 patients with advanced or 
recurrent non-squamous NSCLC were randomized to any of three experimental arms. 
The first two arms were cisplatin + gemcitabine + bevacizumab combination therapy 
with bevacizumab administered at either a high dosage or low dosage. The third arm 
was a placebo comparator where patients were administered cisplatin + gemcitabine + 
placebo. The primary outcome measured was progression-free survival. Efficacy and 
safety were tracked as secondary outcomes. Efficacy was defined as a combination of 
survival duration, time to treatment failure, response rate, and duration of response. 
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Safety was measured through a state-of-the art panel of laboratory values. 
ClinicalTrials.gov Identifier: NCT00806923 
A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based 
Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell 
Lung Cancer 
From 2008 to 2012, 303 patients were administered a combination of 
bevacizumab and carboplatin with either 7.5 mg/kg bevacizumab or 15.0 mg/kg 
bevacizumab. The treatments were being used to treat patients with advanced or 
recurrent non-squamous NSCLC. The primary outcome measured was the percentage 
of patients with either a complete response or partial response. Progression-free 
survival and duration of response were the secondary outcomes measured. 
ClinicalTrials.gov Identifier: NCT00700180 
A Study of Bevacizumab in Combination With First- or Second-Line Therapy in 
Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT) 
Starting in 2006, 115 participants with metastatic non-squamous NSCLC with 
previously treated central nervous system metastases were administered an 
experimental combination of bevacizumab with either first-line or second-line 
chemotherapy. The trial lasted for 3 years. The primary outcome measured was the 
percentage of participants with symptomatic NCI CTCAE (16) Grade ≥ 2 CNS 
hemorrhage. Secondary outcomes measured included patient overall survival and 
adverse effects. ClinicalTrials.gov Identifier: NCT00312728 
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small 
Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis 
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Between 2009 and 2012, 91 patients with stage IV NSCLC were sorted into one 
of two experimental groups. The first group received bevacizumab + carboplatin + 
paclitaxel combination therapy and the second group received bevacizumab + erlotinib 
combination therapy. The primary outcomes measured were progression-free survival 
at 6 months, percentage of participants with disease progression, and time to disease 
progression or death. Secondary outcomes included percentage of patients achieving 
complete response and percentage of patients achieving partial response. 
ClinicalTrials.gov Identifier: NCT00800202 
Effects of Two Doses of rhuMAB-VEGF Antibody in Combination 
w/Chemotherapy in Subjects With Locally Advanced or Metastatic Lung Cancer 
The details and results from this clinical trial were published in 2004 
[https://doi.org/10.1200/JCO.2004.11.022]. In this phase II trial, 99 patients were 
randomly assigned either to bevacizumab + carboplatin + paclitaxel (experimental arm) 
or carboplatin + paclitaxel alone (comparator arm). The primary efficacy measures were 
time to disease progression and best confirmed response rate. ClinicalTrials.gov 
Identifier: N/A 
Safety and Efficacy Study of Avastin in Locally Advanced Metastatic or Recurrent 
Non-small Lung Cancer (NSLC) Participants 
996 participants were enrolled in this study between its start and finish, 2007 and 
2013. Patients were administered several cycles of bevacizumab before beginning 
chemotherapy. After chemotherapy, patients were cycled back to bevacizumab as a 
maintenance therapy. The primary outcome measurement was the percentage of 
patients with adverse effects. Among the secondary outcomes measured were the 
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number of cycles of therapy tolerated, percentage of patients with complete or partial 
response, eastern cooperative group (ECOG) performance status grades, and 
progression free survival. ClinicalTrials.gov Identifier: NCT02596958 
A Study of Bevacizumab Versus Placebo in Combination With 
Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-
Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy 
This randomized, double-blind, placebo-controlled study was conducted between 
2011 and 2017. 276 participants were distributed to either a group receiving 
bevacizumab + carboplatin + paclitaxel (experimental arm) or carboplatin + paclitaxel + 
placebo (active comparator arm). Progression free survival was the primary outcome 
measured, and several survival and lab-value related secondary outcomes were also 
measured. ClinicalTrials.gov Identifier: NCT01364012 
A Study of Avastin in Combination With Chemotherapy for Treatment of 
Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES) 
In the ARIES study, approximately 4,000 patients with locally advanced or 
metastatic NSCLC (or a similar colorectal cancer – CRC), who were also receiving a 
combination bevacizumab therapy, were observed between 2006 and 2012 for disease 
progression. Several data-points were collected over the period to measure safety and 
efficacy of bevacizumab for NSCLC or CRC. The collected data include progression-
free survival and physical tumor biopsies. This study was largely ignored for semi-
mechanistic modeling purposes as it included few tumor measurements. 




Data were received in directories of fully anonymized dataframes (e.g. excel files, 
SAS files, .csvs) organized by general category of data. For initial data processing, data 
were explored for bulk trends, standardized, and unsuitable data were removed. Studies 
were then collated in a single dataframe designed for use with the Monolix suite. 
Between the 11 studies, 3686 patients’ data were determined to be potentially suitable 
for analysis. After exploring the datasets in greater detail, we determined that only 2586 
patients (between the studies) had all the data necessary to create models of tumor 
growth and response – unique patient IDs, a time recorded for each dosing and 
measurement event, tumor measurements, and therapeutic administration details for 
each patient. Data that were unsuitable for analysis were either missing proper 
documentation detailing the contents of the dataframe – e.g. dictionary for column ids – 
or were missing data necessary for longitudinal modeling – e.g. unique patient ids or 
dosing events. 
We chose to model individual tumor longest diameter time-course as our 
independent variable, as the sum of the longest diameter (SLD) typically do not perform 
as well as individual tumor diameter in semi-mechanistic models of tumor growth, and 
individual tumor longest diameter is truer to the biology of the disease {cite}. We were 
not able to separate inter-individual variability (IIV) and inter-occasion variability (IOV) 
resulting from patients with more than 1 tumor being measured. Statistically, all patient-
tumor combinations were treated as unique subject-occasions. This is a biological 
oversimplification, as multiple tumors within a single individual most likely have related 
individual parameters, but this compromise provided a good balance between modeling 
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systems biology and model identifiability. Among the subject-occasions, we had data 
from 6197 unique tumors belonging to 2586 patients. 
After a short period of testing, we imposed several further restrictions on the 
dataset to better facilitate modeling. The first condition was that tumors were required to 
have been measured 3 or more times to qualify for inclusion. This reduced the number 
of unique tumor ids to 4701 and unique individuals to 2036. Then we removed 
monotonic non-responders from the dataset. If for each sample yi,t, for individual i at 
time t, yi,t was greater than or equal to yi,t-1 we labeled the tumor as a monotonic non-
responder and excluded it from the dataset. This reduced the number of individual 
tumors to 4473 and individual ids to 1977. After removing these data, we were left with 
4450 tumors and 1963 individuals. These restrictions imposed on the initial dataset 
representing 2586 patients reduced the number of samples from 29885 to 26515. This 
is an approximate 11% reduction in data. Lastly, because of our limited CPU resources, 
we chose to only work with approximately 5% of the data from each study (randomly 
allocated by subject-tumor pairs). The final dataset used for model building detailed 
tumor growth time-course for 250 individual tumors from 221 patients. 
We also imposed an artificial condition on the lower limit of quantification to 
reduce the chance that noisy measurements would produce numerical instabilities in the 
SAEM search. As an example, in some of the datasets, clinicians would record size = 0 
if they could not find a tumor. If during the next visit, the clinician would find the tumor 
again, the clinician would log a size greater than 0 for the tumor. Records like these 
would occasionally cause convergence issues with the SAEM algorithm. To remedy 
this, we set the lower limit of quantification as 1 mm in diameter. 
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PKPD Model Building 
Individual PK parameters and models were estimated in few of the clinical trials 
used in this study. Therefore, population PK models were collated from various 
publications involving the relevant therapeutics, and IIV was not included in the final PK 
model as it led to structural unidentifiability (Table 5.1). 
As a first step, we wrote our previous model of bevacizumab-
pemetrexed/cisplatin therapy in Mlxtran and validated the model against the dataset 
produced in various treatments receiving any combination of the medications. The units 
of the previous publication were relative to fluorescence, so results were not directly 
translatable. Also, our previous model only dealt with combination bevacizumab-
pemetrexed/cisplatin and we used a simple scaling factor against concentration to 
evaluate effect. This prevented us from being able to validate against other medications. 
We only simulated over short periods in our previous work which made the effects of 
acquired resistance relatively inconsequential, however this effect was readily available 
in various patients within the Vivli dataset. Taken together, this suggested that we first 
start by modifying the Gompertzian growth and cytotoxic kill effect equations to account 
for an expanded set of medications and new units, and later attempt to capture the 
dynamics of resistance. 
To create initial parameterizations for our pharmacodynamic modeling, we 
subsetted to small samples of the full dataset to perform short experiments as well as 
visual exploration. Two primary models were evaluated for the basic description of 
tumor growth and response; (1) the Gompertzian model of tumor growth and (2) the 
Claret model of tumor growth (6,13). As both models are relative to tumor volumes, we 
modeled the tumors as spherical – an oversimplification as tumors are often oblong. 
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Using the Bayesian information criteria as a parsimonious method of cross-evaluating 
models, we found that the Gompertzian model outperformed the Claret model of tumor 
growth at several layers of structural model-building. In the Gompertz model of tumor 
growth (Equation 4), the unperturbed tumor grows at rate α and is exponentially limited 
in growth by parameter β. vc is a scaling factor relating individual tumor cell turnover to 
volume. It was set to 106 cells/mm3 which is the classical assumption of approximate 





= (α ∙ 𝑄α − β ∙ 𝑙𝑜𝑔 (
𝑣
𝑣𝑐
)) ∙ 𝑣 − 𝑄γ ∙ 𝑣 
𝑙𝑜𝑔(𝑄𝛼) = −(1 + 𝑤𝑏𝑒𝑣𝛼 ∙ 𝑐𝑐𝑏𝑒𝑣(𝑡 − τ)) ∙ (𝑒𝑓𝑓𝑚𝑖𝑐𝑟𝑜𝑡 + 𝑒𝑓𝑓𝑣𝑒𝑔𝑓) 




= (α − β ∙ 𝑙𝑜𝑔 (
𝑣
𝑣𝑐
)) ∙ 𝑣 − 𝑄γ ∙ 𝑣 − 𝑄ρ ∙ v + kki ∙ vi ∙ 𝑝 
𝑑𝑣𝑖
𝑑𝑡
= 𝑄𝜌 ∙ 𝑣 − 𝑘𝑘𝑖 ∙ 𝑣𝑖 − 𝑄𝛾 ∙ 𝑣𝑖 
𝑄𝛿 = (1 + 𝑤𝑏𝑒𝑣𝛿 ∙ 𝑐𝑐𝑏𝑒𝑣(𝑡 − 𝜏)) ∙ (𝑒𝑓𝑓𝑚𝑖𝑐𝑟𝑜𝑡 + 𝑒𝑓𝑓𝑣𝑒𝑔𝑓) 
𝑄𝛾 = (1 + 𝑤𝑏𝑒𝑣γ ∙ 𝑐𝑐𝑏𝑒𝑣(𝑡 − τ)) ∙ (𝑒𝑓𝑓𝑝𝑙𝑎𝑡  +  𝑒𝑓𝑓𝑎𝑓𝑜𝑙𝑎𝑡𝑒 + 𝑒𝑓𝑓𝑑𝑟5 + 𝑒𝑓𝑓𝑒𝑔𝑓𝑟 + 𝑒𝑓𝑓𝑑𝑛𝑎𝑠𝑢𝑏) 
In Equation 4a, Qα and Qγ are the antiproliferative effects resulting in growth 
reduction and irreversible cell death, respectively. Chemotherapeutics which acted on 
the microtubules – docetaxel and paclitaxel – along with the direct effect of 
110 
bevacizumab were included in Qα. All other drugs were treated as drugs resulting in 
irreversible cell death. Transient enhancement in efficacy via perfusion normalization by 
bevacizumab was modeled as occurring at time (t – τ) to account for the time delay 
between administration and efficacy enhancement i.e. τ. We found Equation 4a to 
heavily exaggerate the effect of bevacizumab in limiting cell growth rates. To account 
for this, we used a second compartment which represented reversible cell injury, vi, from 
which cells could return from (Equation 4b). Return rate is governed by 
intercompartmental transfer rate kki as well as proportion of repaired cells returned to 
the unperturbed cycle of proliferation, p. We found this better represented the growth 
limiting effects of bevacizumab, paclitaxel, and docetaxel without being as exaggerated 
of an effect as modeled in Equation 4a. 
Irreversible cell death was modeled as occurring over a series of transitions 
between several compartments with intercompartmental transfer rate kk. The final tumor 
volume, a summation of the primary tumor volume and death compartments (z1, z2, and 
z3,) as well as injured cell volume vi, was then transformed to a tumor diameter to match 




= 𝑄𝛾 ∙ 𝑣 − 𝑘𝑘 ∙ 𝑧1 
𝑑𝑧2
𝑑𝑡
= 𝑘𝑘 ∙ 𝑧1 − 𝑘𝑘 ∙ 𝑧2 
𝑑𝑧3
𝑑𝑡
= 𝑘𝑘 ∙ 𝑧2 − 𝑘𝑘 ∙ 𝑧3 
𝑛 = 𝑣 + 𝑧1 + 𝑧2 + 𝑧3 + 𝑣𝑖 





For the pharmacodynamic effect on the tumor growth, we started with a simple 
version of our previous model whereby each drug’s concentration was scaled by a 
single parameter (represented by w for weighting) and the sum of those concentrations 
determined cytotoxic effect (Equation 6a). That proved slightly unstable, so we 
eventually grouped the sum of those effects under an inverse logit function so that their 
sum would be limited. However, this also resulted in parameter instability as there was 
no upper cap on estimates (Equation 6b). After several more iterations of the model, we 
settled on a pharmacodynamic model that individualized drug effects relative to those 
that shared their mechanism of action. We also implemented a model of resistance. In 
this model, the cancer became increasingly more resistant (rate governed by parameter 
λ) to treatment as a function of exposure (AUC) – Equation 6c. A whole diagram of the 
model is available for review in Figure 5.1. 
Equation 6 
(6a) 
𝑒𝑓𝑓𝑑 = (𝑤𝑑 ∙ 𝑐𝑐𝑑) 
𝑒𝑓𝑓𝑡𝑜𝑡𝑎𝑙 = ∑𝑤𝑑 ∙ 𝑐𝑐𝑑 
𝑑 ∈  𝑐𝑖𝑠, 𝑐𝑎𝑟, 𝑝𝑒𝑚, 𝑎𝑝𝑜, 𝑒𝑟𝑙, 𝑔𝑒𝑚, 𝑝𝑎𝑐, 𝑑𝑜𝑐, 𝑏𝑒𝑣 
(6b) 
𝑒𝑓𝑓𝑑 = (𝑤𝑑 ∙ 𝑐𝑐𝑑) 
𝑒𝑓𝑓𝑡𝑜𝑡𝑎𝑙 = γ ∙ (𝑖𝑛𝑣𝑙𝑜𝑔𝑖𝑡 (∑𝑤𝑑 ∙ 𝑐𝑐𝑑) − 0.5) 





𝐴𝑈𝐶𝑑  =  ∫ 𝑐𝑐𝑑(𝑡) 
[
𝑠𝑖𝑛𝑔𝑙𝑒 𝑑𝑟𝑢𝑔 𝑒𝑓𝑓  ≡  𝑙𝑜𝑔(𝑒𝑓𝑓𝑚) = 𝑙𝑜𝑔(𝑤𝑑 ∙ 𝑐𝑐𝑑) − (λ𝑑 ∙ 𝐴𝑈𝐶𝑑)
𝑝𝑎𝑖𝑟𝑒𝑑 𝑑𝑟𝑢𝑔 𝑒𝑓𝑓  ≡   𝑙𝑜𝑔(𝑒𝑓𝑓𝑚) = 𝑙𝑜𝑔 (𝑤𝑑1−𝑟𝑒𝑙−2(𝑐𝑐𝑑1 + 𝑤𝑑2𝑐𝑐𝑑2)) − λ𝑑1−𝑟𝑒𝑙−2(𝐴𝑈𝐶𝑑1 + λ𝑑2𝐴𝑈𝐶𝑑2)
] 
𝑑 ∈ 𝑐𝑖𝑠, 𝑐𝑎𝑟, 𝑝𝑒𝑚, 𝑎𝑝𝑜, 𝑒𝑟𝑙, 𝑔𝑒𝑚, 𝑝𝑎𝑐, 𝑑𝑜𝑐, 𝑏𝑒𝑣 
𝑚 ∈  𝑝𝑙𝑎𝑡, 𝑎𝑓𝑜𝑙𝑎𝑡𝑒, 𝑑𝑟5, 𝑒𝑔𝑓𝑟, 𝑑𝑛𝑎𝑠𝑢𝑏,𝑚𝑖𝑐𝑟𝑜𝑡, 𝑣𝑒𝑔𝑓 
Individual variability was modeled using the standard log-link formulation and 
initial tumor volumes were fixed to the measurement of the tumor at time 0, relative for 
each individual. The only except was parameter p which was fixed between 0 and 1 
using a logit-link function (Equation 7). Measurement error was modeled using the 
equation titled combined 1 in Monolix, i.e. a single additive term (a) added with a single 
proportional term (b). 
Equation 7 
log-link: 𝜙𝑖 = 𝜙𝑝𝑜𝑝 ∙ 𝑒
𝜂𝑖 
logit-link: 𝑙𝑜𝑔𝑖𝑡(𝜙𝑖) = 𝑙𝑜𝑔𝑖𝑡(𝜙𝑝𝑜𝑝) + η_𝑖 
𝑣(𝑡 = 0) = 𝑦(𝑡 = 0) 
Model Diagnostics 
 Our model diagnostics suggest a stable and precise fit that largely fits the 
assumptions necessary to draw conclusions. We observed that the SAEM search was 
stable and reliable when estimating our final set of parameter estimates (Figure 5.2). 
We were not able to perform a full convergence assessment because of computational 
constraints, but our experiments in subsets of the data suggest that results are stable 
regardless of relative initial parameter estimates. Individual fits were reasonably 
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descriptive with both a well described response and rebound after treatment cessation 
(Figure 5.3). After seeing evidence of correlations (via Pearson’s test) between 
individual effects, we inspected those correlations using the full posterior plot of 
individual effects in parameter ηL vs ηK where L is not equal to K. We found that though 
correlations existed, the slope of the correlations was nearly zero and they were likely 
just natural artifacts that appear when working with large datasets (increased statistical 
power). An even spread of observations vs. individual predictions suggests that our 
model has no major structural misspecifications and that our error model was well 
specified (Figure 5.4). However, formal tests for residual normality and centering on 
zero failed. This is likely because of our use of the initial measured tumor volume as a 
covariate (residual is equal to 0) and the artificial implementation of a universal lower 
limit of quantification (observations fixed to 0.1). Once removing the censored points 
and the points measured at time 0, our residual error model aligns much more closely 
with the theoretical model. Precision of parameter estimates is extremely high with low 
dependency between estimates. Full parameter estimates, IIV, and RSEs are reported 
in Table 2. The visual predictive check (VPC) was informative as to wholistic model 
performance. Although the clinical trials were not matched, the VPC still indicates 
overall high-quality fit (Figure 5.4). Spread of individual parameters meets the 
Kolmogorov-Smirnov test for normality. 
Clinical Trial Simulations 
In our clinical trial simulations, we found an unexpected result. When we 
simulated the exact conditions of the clinical trial, but with a gap that was varied 
between administering bevacizumab 5 days earlier than scheduled and 5 days later 
than scheduled (at steps of 1 days), we found almost no difference between treatment 
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groups. Put another way, administering bevacizumab before cytotoxics did not increase 
efficacy as expected (Figure 5.5 and Table 5.3). 
We wanted to further investigate this outcome, so we simulated a human analog 
of our 2018 trial in mice using the full posterior distribution as estimated in Monolix as a 
virtual population pool. We largely found the same result (Figure 5.6 and Table 5.4). 
As one last test, we began simulating individual IDs and comparing the outcome 
at various gaps from administering bevacizumab 5 days earlier to administering 
bevacizumab 5 days later. Explored in this way, it became clear that administering 
bevacizumab before pemetrexed/cisplatin did produce a significant effect in some 
patients, but not in all (Figure 5.7). 
Discussion 
Our primary goal for this project was building a comprehensive semi-mechanistic 
model of NSCLC growth and response to various clinical anti-proliferatives. To that end, 
we have largely been successful in developing a model to explain the variation we see 
in the data. Our model captures the antiproliferative effects of the 11 different 
therapeutics used across the clinical trials as well as intrinsic and acquired resistance. 
We have pooled the best available and published pharmacokinetic models of the 
therapeutics involved, and we have used population estimates for each individual 
patient. This compromise likely slightly inflates the estimates of pharmacodynamic 
variation. Guided by our previous findings, we were also able to capture the transient 
enhancement of perfusion resulting from anti-VEGF therapy (bevacizumab). Individual 
predictions are relatively precise and our model captures the well-described rebound in 
growth after treatment cessation in non-small cell lung cancer. 
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We have also built that model with several innovations from our previous efforts. 
We have used AUC as a measure of exposure to model acquired resistance. Intrinsic 
resistance has been folded into the distribution of wd (i.e. weighting) terms in our system 
of equations. We also found that having a second cytotoxic effect for reversible cellular 
injury allowed us to capture direct effects of bevacizumab as well as capture the effect 
of medications known to cause reversible cell injury (i.e. paclitaxel and docetaxel). Our 
largely modular form of differential equations also provides a natural avenue for adding 
more drugs to the model. We have also provided a robust set of parameter estimates 
and have made our model code freely available for future research in non-small cell 
lung cancer. 
When evaluating our model, we found robust evidence to support our choice of 
model structure. Parameter estimates and individual predictions were made with 
relatively high precision. This is likely due to the largeness of the dataset included. 
Model structure was based on biological mechanisms making interpretation of 
parameters relatively natural – e.g. λ parameters define the rate of acquired resistance 
vs. exposure – and lending the model the longevity afforded by mechanistic modeling. 
On parameter estimate interpretation, we have used relatively simple naming heuristics 
to aid in interpretation. As stated above, λ parameters define the rate of acquired 
resistance vs. exposure. wd parameters weight drug action against the tumor i.e. the 
larger the wd parameter, the larger the action the drug takes proportional to both the 
tumor size and concentration of the drug in plasma. The parameter titled imv_r_perc 
indicates the proportion of cells in the injured volume which return to unperturbed tumor 
growth. Unperturbed tumor growth is governed by parameters α, exponential rate of 
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growth of tumor, and β, exponential rate of decrease in growth rate due to nutrient 
supply limitations. 
 We acknowledge several weaknesses in our approach which must be addressed 
in future studies. Due to limited computing resources and poor documentation, we were 
unable to work with larger (approaching 95%) portions of the dataset. The model was 
not validated against data not used in training the fit. In the future, we will use 
individualized Bayesian predictions based on initial measurements of tumor growth and 
response to test if our model can make accurate predictions of the observed late stages 
of response. We also have a large amount of data on cutting-edge first-line therapies 
i.e. pembrolizumab and other immune-checkpoint inhibitors. This data was granted to 
us through a sub-request, and has not been able to be included in this modeling project. 
There are also several covariates which have not been included or tested in the model. 
To make individual predictions meaningful, they must be matched against patient 
characteristics and lab values. 
One of the primary features we hoped to capture with our model was the 
transient enhancement of drug delivery after bevacizumab administration. Theoretically, 
this transient enhancement would drive the synergism between bevacizumab and other 
antiproliferatives. A natural conclusion, and a conclusion supported by previously 
published clinical papers, is that administering bevacizumab before other 
antiproliferatives should result in the greatest reduction in tumor size. Unexpectedly, we 
found through simulation that this result is only true in some cases. Moreover, in some 
individuals, delaying the bevacizumab until after other therapeutics provided the 
greatest reduction in tumor volume. Why this is so is not readily suggested by the model 
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developed in this study. To solve this problem, our research group will simulate more 
clinical trials to determine if there is parameter clustering or some covariate which might 
predict what the optimal gap in any given patient might be. 
Making individual predictions is the long-term goal for this modeling project. This 
first phase of research was meant to establish a robust preliminary model structure 
which explained a great deal of variation in the data. Expanding our dataset past 5% of 
the cleanest data, including covariates and individual patient characteristics, using 
simulation to find what might predict ultimate gap between bevacizumab and 
combination antiproliferatives, and refining the structure of our model will give us the full 
set of tools to develop tools to take individual patient data, and from that data 
individualize therapy. 
Tables and Figures  
 
Table 5.1 Pharmacokinetic Parameters 
Therapeutic V1 V2 V3 Q1 Q2 k12 k21 Cl Source 
Units mL mL mL mL/day mL/day day–1 day–1 mL/day - 
bevacizumab 2804.12 - - - - 0.223 0.215 216.291 (17) 
cisplatin 22300 77000 - 456000 - - - 6480 (18) 
pemetrexed 12900 3380 - 20736 - - - 131904 (19) 
apomab* 3970 3840 - 793 - - - 328 (20) 
paclitaxel  229000 856000 30300 3216000 5112000 - - 10296000 (21) 
carboplatin 11900 8230 - 2172000 - - - 177120 (22) 
gemcitabine 15000 15000 - 1008000 - - - 3888000 (23) 
docetaxel  7900 - - - - 27.12 3.6 723120 (24) 
erlotinib† 210000 - - - - - - 102960 (25) 








Table 5.2 Pharmacodynamic Parameters 





alpha_pop 0.17 0.0045 2.65 
beta_pop 0.024 0.00047 1.95 
tau_pop 0.37 0.013 3.39 
kk_pop 0.0069 0.0013 19.4 
w_cis_rel_pop 0.52 0.059 11.3 
w_car_pop 0.82 0.054 6.53 
w_pem_pop 0.87 0.063 7.32 
w_apo_pop 0.78 0.022 2.87 
w_erl_pop 0.66 0.025 3.77 
w_gem_pop 0.95 0.05 5.27 
w_pac_rel_pop 0.85 0.043 5.09 
w_doc_pop 0.93 0.019 2 
w_bev_pop 1.78 0.29 16.6 
lambda_cis_rel_pop 0.001 0.000023 2.23 
lambda_car_pop 0.0013 0.000092 7.14 
lambda_pem_pop 0.0009 0.000039 4.37 
lambda_apo_pop 0.00072 0.000014 1.9 
lambda_erl_pop 0.0012 0.00011 8.99 
lambda_gem_pop 0.0014 0.00005 3.69 
lambda_pac_rel_pop 0.00088 0.000048 5.49 
lambda_doc_pop 0.0011 0.000051 4.74 
lambda_bev_pop 0.0039 0.00068 17.2 
w_bev_gamma_pop 1.03 0.051 4.94 
w_bev_rho_pop 2.05 0.26 12.7 
kk_i_pop 0.0099 0.0025 25.2 
imv_r_perc_pop 0.3 0.058 19.5 
    
Standard Deviation of the Random Effects 
omega_alpha 0.32 0.02 6.38 
omega_beta 0.23 0.016 7.11 
omega_tau 0.35 0.033 9.48 
omega_kk 2.06 0.16 7.55 
omega_w_cis_rel 1.12 0.11 9.87 
omega_w_car 0.61 0.059 9.65 
omega_w_pem 0.7 0.061 8.79 
omega_w_apo 0.27 0.026 9.47 
omega_w_erl 0.36 0.32 8.96 
omega_w_gem 0.51 0.042 8.29 
omega_w_pac_rel 0.47 0.055 11.8 
omega_w_doc 0.2 0.016 7.89 
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Table 5.2 continued 





omega_w_bev 1.95 0.14 7.32 
omega_lambda_cis_rel 0.22 0.02 8.99 
omega_lambda_erl 0.9 0.087 9.66 
omega_lambda_gem 0.37 0.035 9.51 
omega_lambda_pack_rel 0.49 0.05 10.2 
omega_lambda_doc 0.48 0.043 9.07 
omega_lambda_bev 1.8 0.12 6.6 
omega_w_bev_gamma 0.47 0.044 9.36 
omega_w_bev_rho 1.17 0.12 9.98 
omega_kk_i 3.1 0.26 8.29 
omega_imv_r_perc 2.85 0.24 8.52 
    
Error Model Parameters 
a 0.11 0.008 7.57 
b 0.088 0.0054 6.13 
 
 
Table 5.3 Summary of Simulation Outcomes 1  
In this simulated experiment, all patients fit during the course of the study were 
simulated again, except this time bevacizumab was administered between 5 and 0 days 
before the primary medication (m5 through c0) or between 0 and 5 days after the 
primary medication (c0 through p5). Below are the minimum, 5th percentile, median, 
95th percentile, and maximum of the minimum tumor volume relative to baseline, e.g. in 
the c0 group, the median tumor reduction was by 69%. 
  min P05 Median P95 Max 
m5 0 0.00081 0.3 0.88 1.12 
m4 0 0.00014 0.3 0.88 1.12 
m3 0 0.000028 0.29 0.88 1.12 
m2 0 0.00084 0.29 0.88 1.16 
m1 0 0.0012 0.3 0.88 1.21 
c0 0 0 0.31 0.88 1.25 
p1 0 0.0011 0.31 0.88 1.3 
p2 0 0.0017 0.31 0.88 0.135 
p3 0 0.0017 0.3 0.89 1.39 
p4 0 0.0019 0.3 0.89 1.44 





Table 5.4 Summary of Simulation Outcomes 2 
In this simulated experiment, bevacizumab pemetrexed and cisplatin were administered 
at recommended dosages to virtual patients every 21 days for 4 cycles. The gap 
between bevacizumab and pemetrexed/cisplatin administration was set at either 5 days 
(m5), 3 days (m3), 1 day (m1), 0 days (c0), or pemetrexed/cisplatin was administered 
either 1 day (p1) or 2 days (p2) before bevacizumab. Below are the minimum, 5th 
percentile, median, 95th percentile, and maximum of the minimum tumor volume relative 
to baseline, e.g. in the c0 group, the median tumor reduction was by 39% 
 
min P05 Median P95 Max 
m5 0 0.11 0.65 1 1.07 
m3 0 0.13 0.63 1 1.07 
m1 0 0.15 0.61 1 1.09 
c0 0 0.16 0.6 1 1.09 
p1 0 0.16 0.59 1 1.09 
p2 0 0.16 0.59 1 1.09 
 
 
Figure 5.1 Model Diagram 
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Figure 5.2 SAEM Search 
Stochastic approximation expectation maximization search for most likely estimates of 
parameter values. Exploratory search in black and smoothing search in red. 
 
 
Figure 5.3 Sample of Individual Fits  




Figure 5.4 Observations vs. Predictions by Patients Receiving Therapeutic  
In these figures the observations vs predictions (black points) are plotted along with 
censored data (red points). Blue line is where observations meet predictions i.e. ratio is 
1. Error model 95% prediction boundaries at dotted red lines. Points are 




Figure 5.5 Visual Predictive Check 
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Figure 5.6 Summary of Simulation Outcomes with Box and Whiskers Plots 1 
In this simulated experiment, all patients fit during the course of the study were 
simulated again, except this time bevacizumab was administered between 5 and 0 days 
before the primary medication (m5 through c0) or between 0 and 5 days after the 
primary medication (c0 through p5). The horizontal red lines are reference lines to the 
1st, 2nd, and 3rd quartile for the simulated trial where gap was equal to zero. 
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Figure 5.7 Summary of Simulation Outcomes with Box and Wiskers Plots 2 
In this simulated experiment, bevacizumab pemetrexed and cisplatin were administered 
at recommended dosages to virtual patients every 21 days for 4 cycles. The gap 
between bevacizumab and pemetrexed/cisplatin administration was set at either 5 days 
(m5), 3 days (m3), 1 day (m1), 0 days (c0), or pemetrexed/cisplatin was administered 
either 1 day (p1) or 2 days (p2) before bevacizumab. The horizontal red lines are 
reference lines to the 1st, 2nd, and 3rd quartile for the simulated trial where gap was 




Figure 5.8 A Pair of Illustrative Examples 
In this simulated experiment, bevacizumab pemetrexed and cisplatin were administered 
at recommended dosages to virtual patients every 21 days for 4 cycles. The gap 
between bevacizumab and pemetrexed/cisplatin administration was set at either 5 days 
(m5), 3 days (m3), 1 day (m1), 0 days (c0), or pemetrexed/cisplatin was administered 
either 1 day (p1) or 2 days (p2) before bevacizumab. For the virtual patient with a larger 
final tumor volume, administering bevacizumab after pemetrexed/cisplatin produces the 
maximum tumor volume reduction. However, the opposite is true of the virtual patient 
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CHAPTER 6.    GENERAL CONCLUSION 
Developing clinical therapeutics that are broadly effective in NSCLC is extremely 
challenging due to the idiosyncrasies of individualizing therapies which are often 
developed in small and noisy sample sets which are unrepresentative of the general 
population. Therapeutics that are approved for use in NSCLC are usually only effective 
in a small subset of the population – at their approved dosage and recommended 
scheduling. Individual patient characteristics and the patients’ cancer characteristics 
determine the viability of various treatments. And Although a therapeutic might initially 
be helpful, there is always the eventuality that the drug becomes intolerable to the 
patient or that their cancer develops resistance. As of yet, medical doctors cannot 
reliably individualize cancer therapy to meet the needs of every patient. Instead, doctors 
use insight gained from their clinical experience, in combination with formal 
recommendations from accredited institutions, to guide their choices when treating 
individual patients. The greatest aspiration of mathematical modelers in NSCLC is to 
create robust tools that clinicians can use in their daily practice to assist them in 
selecting the right therapeutics at the right dosages in the right patient populations. To 
build those tools, a thorough mathematical and biological understanding of NSCLC 
growth and response to anti-proliferatives will be necessary. 
Throughout these research projects we have been attempting to create 
comprehensive, semi-mechanistic mathematical descriptions of various anti-NSCLC 
therapies. We have built these models using a variety of heuristics. A common starting 
place in pharmaceutical modeling projects is to reference the literature for previous 
efforts. Hopefully, one can use a previously published model as a base structure or gain 
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an understanding of the most prominent biological features. If the modeling project is 
novel, simple mammillary compartmental models and exponential-family functions can 
be arranged to produce a rough empirical fit. The base model structure is used as a 
platform for developing a more sophisticated description, but the model must be 
informed with data. This data can either be produced experimentally in a preclinical or 
clinical environment, it can be collated from previously published studies and clinical 
trials, or it can be simulated directly if the biology is sufficiently well understood. After 
fitting a base model, the structure can be refined systematically until the model 
sufficiently explains the variation in the data. Then, final parameter estimates are 
derived from the dataset and the model is said to be fit or parameterized. A fit model 
can then be used to simulate various clinical trials to answer questions of interest to the 
research group. After publishing results and the data used to derive them, other 
members of the research community can structurally improve the NLME model or use 
the final parameterization for simulation.  
Those heuristics have been implemented throughout the publications collated in 
this document. In Chapter 2, we outline a perspective for solving problems in PKPD 
modeling which emphasizes the development of spontaneous-disease animal models. 
In Chapter 3, we detail the PKPD of pharmacological ascorbate for cancer and build a 
modeling framework based on mamillary compartmental models which will be reusable 
in future studies in either preclinical, clinical, or veterinary environments. In Chapter 4, 
we built a translational model of bevacizumab-pemetrexed/cisplatin for NSCLC. We 
used the structure of a previously published NLME model in the study. We fit the model 
using data from a xenograft model of NSCLC. Lastly, in Chapter 5, we took preliminary 
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findings from Chapter 4 and used them to build a clinical model of anti-NSCLC therapy. 
Our final model developed in Chapter 5 was a combination of various biological 
mechanisms of the therapeutics, and previously published pharmacokinetics and 
pharmacodynamics models, as well as our previous work in bevacizumab-
pemetrexed/cisplatin. The data used to fit the model was collated from several large 
clinical trials in anti-NSCLC therapy. 
NLME modeling is a natural framework for solving problems in pharmacokinetics. 
When a patient is administered a medication, researchers cannot take samples at 
frequent time intervals without significantly perturbing the system, or worse, 
endangering the health of the patient. NLME modeling excels in sparse sampling 
regimens when the inter-individual variation and error from measurements are relatively 
regular. NLME modeling also gives a logical structure to analyze the variation in the 
estimates you derive when the model is fit. The researcher describes individual variation 
in terms of some theoretical population center relative to various covariates. In most 
diseases, the NLME approach is also well-suited to the pharmacodynamics modeling 
for much the same reasons. 
There is a necessary deductive aspect of modeling anti-NSCLC therapy. As of 
yet, there is no method for reliably and frequently measuring the volume of NSCLC 
tumors. Contrarily, a unique facet of NSCLC modeling is that direct samples of the 
tumor are taken at exceptionally long intervals relative to almost any other disease. And, 
the samples that are produced are usually heavily affected by measurement error. 
Clinicians use a great variety of techniques – from physical calipers to CT scans – to 
measure tumor volumes. In many studies, tumor volumes are not even recorded. Often, 
133 
clinicians simply approximate the tumor burden by working with the longest diameters of 
the largest tumors. And, the time-of-day of measurement is usually considered 
irrelevant and left out of records. Trials in clinical therapeutics are also typically 
coordinated between many different treatment centers and research groups. These 
various groups tend to have minor variations in laboratory protocols, further adding to 
the total error in the dataset. Lastly, because cancer usually develops as a cascade of 
mutations, there is high variability between patients in cancer pathology. Consequently, 
modelers in NSCLC, and in cancer generally, use a combination of sparse samples, 
biomarkers of tumor growth and response, and time-to-death to develop an empirical 
semi-mechanistic understanding of the largely latent process that is cancer progression. 
The logic underlying this modeling strategy is that when variability is relatively regular, 
each datapoint puts constraints on the possible solutions to the structural model 
describing the latent process. With enough datapoints and a simple enough model, the 
modeler should theoretically be able to identify a set of parameters which largely 
accounts for the variability in the data. 
Perspectives and Next Steps 
In the final study reproduced in this document, Chapter 5, we collated several 
datasets from 11 intensively-sampled clinical trials in NSCLC to develop a generalized 
platform for modeling in NSCLC. The basic motivation behind this study was that with a 
big enough dataset, and the model structure developed in Chapter 4, we believed that it 
might be possible for us to produce a robust and reusable description of NSCLC growth 
and response to various antiproliferative therapies. In the course of fitting that model, 
we found the population variability quite difficult to describe and the datapoints following 
inexplicable time-courses. This is, at least in part, because the datasets contained many 
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clear errors and physiologically improbable events –as a hypothetical example: tumor 
diameter fluctuating from 1.0 cm in January, to 2.0 cm in June, and 0.0 cm in July, 
before climbing to 4.0 cm in August. Patients also commonly miss or must reschedule 
visits, making measurement intervals erratic. And as a final note, tumor measurements 
with CT scans, ultrasounds, calipers, etc. require the involvement of a medical doctor. 
This puts a large cost burden on the study sponsors as well as patients. That cost 
burden perversely incentivizes a minimal sampling schedule with rudimentary methods. 
If, in the future, we want to fully leverage the potential of mathematical modeling to 
solve problems in NSCLC, it seems clear to me that the best place to innovate is not in 
intelligently designed statistics or clever computer algorithms, but in developing more 
robust procedures for measurement.  
